BUKTI SUBMIT MANUSKRIP

PENULIS MERUPAKAN PENULIS PERTAMA DAN SELALU BERKOMUNIKASI DENGAN KOREPONDING AUTHOR SELAMA PROSES PUBLIKASI, SEBAGAIMANA TERLAMPIR

Universitas Hasanuddin

Andi Dian Permana <andi.dian.permana@farmasi.unhas.ac.id>

ACS Applied Materials & Interfaces - Manuscript ID am-2021-111796

1 message

ACS Applied Materials & Interfaces <onbehalfof@manuscriptcentral.com> Tue, Jun 15, 2021 at 10:55 PM

Reply-To: support@services.acs.org
To: r.donnelly@qub.ac.uk
Cc: andi.dian.permana@farmasi.unhas.ac.id, a.paredes@qub.ac.uk, f.volpezanutto@qub.ac.uk, nuramir@unhas.ac.id, ismail@unhas.ac.id, akbarbahar@unhas.ac.id, sumarheni@unhas.ac.id, sdpalma@unc.edu.ar, r.donnelly@qub.ac.uk

15-Jun-2021

Journal: ACS Applied Materials & Interfaces
Manuscript ID: am-2021-111796
Title: "Albendazole nanocrystal-based dissolving microneedles: A promising approach for intradermal delivery with improved pharmacokinetic performance for enhanced treatment of cystic echinococcosis"
Authors: Permana, Andi Dian; Paredes, Alejandro J.; Zanutto, Fabiana Volpe; Amir, Muh. Nur; Ismail, Ismail; Bahar, Muh. Akbar; Sumarheni, Sumarheni; Palma, Santiago Daniel; Donnelly, Ryan F.
Manuscript Status: Submitted

Dear Dr. Donnelly:

Your manuscript has been successfully submitted to ACS Applied Materials & Interfaces.

Please reference the above manuscript ID in all future correspondence or when calling the office for questions. If there are any changes in your contact information, please log in to ACS Paragon Plus with your ACS ID at http://paragonplus.acs.org/login and select "Edit Your Profile" to update that information.

You can view the status of your manuscript by checking your "Authoring Activity" tab on ACS Paragon Plus after logging in to http://paragonplus.acs.org/login.

Journal Publishing Agreement and Copyright

Upon acceptance, ACS Publications will require the corresponding author to sign and submit a Journal Publishing Agreement. This agreement gives authors a number of rights regarding the use of their manuscripts. At acceptance, the corresponding author will receive an email linking through to the Journal Publishing Agreement Wizard, which helps you select the most appropriate license for your manuscript.

For more information please see: https://pubs.acs.org/page/copyright/journals/jpa_faqs.html

ACS Authoring Services

Did you know that ACS provides authoring services to help scientists prepare their manuscripts and communicate their research more effectively? Trained chemists with field-specific expertise are available to edit your manuscript for grammar, spelling, and other language errors, and our figure services can help you increase the visual impact of your research.

Visit https://authoringservices.acs.org to see how we can help you! Please note that the use of these services does not guarantee that your manuscript will be accepted for publication.

Thank you for submitting your manuscript to ACS Applied Materials & Interfaces.

Sincerely,

Dr. Kirk Schanze

ACS Applied Materials & Interfaces

BUKTI REVIEW DARI REVIEWERS

Universitas Hasanuddin

Andi Dian Permana <andi.dian.permana@farmasi.unhas.ac.id>

Fwd: Revision Requested for Manuscript ID am-2021-111796

1 message

Andi Permana <apermana01@qub.ac.uk> Fri, Apr 7, 2023 at 10:08 PM
To: Andi Dian Permana <andi.dian.permana@farmasi.unhas.ac.id>

Get Outlook for iOS

From: Ryan Donnelly <R.Donnelly@qub.ac.uk>
Sent: Wednesday, July 7, 2021 10:20:51 PM
To: Andi Permana <apermana01@qub.ac.uk>; Alejandro Paredes <A.Paredes@qub.ac.uk>; Fabiana Volpe Zanutto <F.VolpeZanutto@qub.ac.uk>
Subject: Fw: Revision Requested for Manuscript ID am-2021-111796

Have a look guys,

A lot of Qs, but this should be accepted.

Happy to discuss.

Well done.

Ryan

Professor Ryan F. Donnelly
Chair in Pharmaceutical Technology
School of Pharmacy
Queen's University Belfast
Medical Biology Centre
97 Lisburn Road
Belfast
BT9 7BL
UK
Tel: +44 (0) 2890 972 251
Fax: +44 (0) 2890 247 794
Email: r.donnelly@qub.ac.uk

From: ACS Applied Materials & Interfaces <onbehalfof@manuscriptcentral.com>
Sent: 07 July 2021 15:16
To: Ryan Donnelly <R.Donnelly@qub.ac.uk>
Subject: Revision Requested for Manuscript ID am-2021-111796

07-Jul-2021

Journal: ACS Applied Materials & Interfaces
Manuscript ID: am-2021-111796
Title: "Albendazole nanocrystal-based dissolving microneedles: A promising approach for intradermal delivery with improved pharmacokinetic performance for enhanced treatment of cystic echinococcosis"
Author(s): Permana, Andi Dian; Paredes, Alejandro; Zanutto, Fabiana Volpe; Amir, Muh. Nur; Ismail, Ismail; Bahar, Muh. Akbar; Sumarheni, Sumarheni; Palma, Santiago Daniel; Donnelly, Ryan F.

COVID-19 Support: Please visit the following website to access important information for ACS authors and reviewers during the COVID-19 crisis: https://eur02.safelinks.protection.outlook.com/?url=https%3A%2F%2Faxial.acs.org%2F2020%2F03%2F25%2Fchemists-covid-19-coronavirus%2F&data=04%7C01%7CR.Donnelly%40qub.ac.uk%7C4d50803dc86040b3f59408d94151d946%7Ceaab77eab4a549e3a1e8d6dd23a1f286%7C0%7C0%7C637612642210691094%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C1000&sdata=CKmcvofKxoBJW7CVneDpRJnJ5ZHuzHLkji3SEGvXQl0%3D&reserved=0

We are flexible in these unprecedented times affecting the global research community. If you need more time to complete authoring or reviewing tasks, please contact the editorial office and request an extension.

Dear Dr. Donnelly:

Thank you for submitting your manuscript for publication in ACS Applied Materials & Interfaces. The reviewer comments for the above-referenced manuscript are enclosed for your information. The reviewers indicate that the manuscript requires major revision to address a number of specific points before it can be published.

On the basis of the reviewer comments and my own assessment of the manuscript, I am willing to consider a revised version of this paper for publication in ACS Applied Materials & Interfaces pending a second round of external review. In preparing the revision, carefully consider all of the comments made by the reviewers.

We would like to receive your revision as soon as possible, by 28-Jul-2021 at the latest.

In addition to addressing the reviewers' comments, please make sure that your manuscript addresses the following issues:

1) Funding Sources: Authors are required to report ALL funding sources and grant/award numbers relevant to this manuscript. Enter all sources of funding for ALL authors relevant to this manuscript in BOTH the Open Funder Registry tool in ACS Paragon Plus and in the manuscript to meet this requirement. See https://eur02.safelinks.protection.outlook.com/?url=http%3A%2F%2Fpubs.acs.org%2Fpage%2F4authors%2Ffunder_options.html&data=04%7C01%7CR.Donnelly%40qub.ac.uk%7C4d50803dc86040b3f59408d94151d946%7Ceaab77eab4a549e3a1e8d6dd23a1f286%7C0%7C0%7C637612642210691094%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C1000&sdata=EwqIVqW%2BVOjQhfkUiHG5GH349ymQ2nEZ7paFnBDEYWw%3D&reserved=0 for complete instructions.

2) ORCID: Authors submitting manuscript revisions are required to provide their own validated ORCID iDs before completing the submission, if an ORCID iD is not already associated with their ACS Paragon Plus user profiles. This iD may be provided during original manuscript submission or when submitting the manuscript revision. You can provide only your own ORCID iD, a unique researcher identifier. If your ORCID iD is not already validated and associated with your ACS Paragon Plus user profile, you may do so by following the ORCID-related links in the Email/Name section of your ACS Paragon Plus account. All authors are encouraged to register for and associate their own ORCID iDs with their ACS Paragon Plus profiles. The ORCID iD will be displayed in the published article for any author on a manuscript who has a validated ORCID iD associated with ACS Paragon Plus when the manuscript is accepted. Learn more at https://eur02.safelinks.protection.outlook.com/?url=http%3A%2F%2Fwww.orcid.org%2F&data=04%7C01%7CR.Donnelly%40qub.ac.uk%7C4d50803dc86040b3f59408d94151d946%7Ceaab77eab4a549e3a1e8d6dd23a1f286%7C0%7C0%7C637612642210691094%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C1000&sdata=mJ70YVknpzamDPgcOAodg2PGS1LVnUTCQ1cOOnPy2rE%3D&reserved=0.

3) ***Please note that you may receive a follow-up message within one business day describing the non-scientific changes you must also make to your manuscript before you submit the revision.

4) On resubmission, please provide 2 copies of the final manuscript file:
a) The final revised manuscript file that does not contain any highlighting or editing marks. This file should be uploaded as the primary manuscript document file.
b) A marked copy of the revised manuscript that shows changes made on revision clearly highlighted. This file should be uploaded SEPARATELY FROM THE FINAL MANUSCRIPT FILE as Supporting Information for Review.

c) Do not add any highlighting or other editing marks to the supporting information file that is intended to be published with the manuscript (this file is uploaded as "supporting information for publication").

To revise your manuscript, log into ACS Paragon Plus with your ACS ID at https://eur02.safelinks.protection.outlook.com/?url=http%3A%2F%2Fparagonplus.acs.org%2Flogin&data=04%7C01%7CR.Donnelly%40qub.ac.uk%7C4d50803dc86040b3f59408d94151d946%7Ceaab77eab4a549e3a1e8d6dd23a1f286%7C0%7C0%7C637612642210691094%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C1000&sdata=yACjWzxax4KNMyNOB2XJVGflvC1LUYsT4yFxS3%2BEiOg%3D&reserved=0 and select "My Authoring Activity". There you will find your manuscript title listed under "Revisions Requested by Editorial Office." Your original files are available to you when you upload your revised manuscript. If you are replacing files, please remove the old version of the file from the manuscript before uploading the new file.

When submitting your revised manuscript through ACS Paragon Plus, you will be able to respond to the comments made by the reviewer(s) in the text box provided or by attaching a file containing your detailed responses to all of the points raised by the reviewers.

Please make sure your manuscript adheres to the formatting specifications of ACS Applied Materials & Interfaces. The instructions are available to authors using the following url: https://eur02.safelinks.protection.outlook.com/?url=http%3A%2F%2Fpubs.acs.org%2Fpage%2Faamick%2Fsubmission%2Fauthors.html&data=04%7C01%7CR.Donnelly%40qub.ac.uk%7C4d50803dc86040b3f59408d94151d946%7Ceaab77eab4a549e3a1e8d6dd23a1f286%7C0%7C0%7C637612642210691094%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C1000&sdata=fwsONh%2BfIurpdnL%2B%2FxRhv7ngUScbU1YNUKEJOq1vmSM%3D&reserved=0

You may also find it helpful to look at the online version of the journal at https://eur02.safelinks.protection.outlook.com/?url=http%3A%2F%2Fpubs.acs.org%2Fjournal%2Faamick&data=04%7C01%7CR.Donnelly%40qub.ac.uk%7C4d50803dc86040b3f59408d94151d946%7Ceaab77eab4a549e3a1e8d6dd23a1f286%7C0%7C0%7C637612642210691094%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C1000&sdata=7o9S%2B5CnTwAkcjhyTYIZLMN2VpNwrXzjk10Qk%2BYvd2w%3D&reserved=0.

Thank you for considering ACS Applied Materials & Interfaces as a forum for the publication of your work.

ACS Publications uses Crossref Similarity Check Powered by iThenticate to detect instances of similarity in submitted manuscripts. In publishing only original research, ACS is committed to deterring plagiarism, including self-plagiarism. Your manuscript may be screened for similarity to published material.

With sincere regards,

Prof. Albena Ivanisevic
Associate Editor
ACS Applied Materials & Interfaces
Fax: 12023509587
email: ivanisevic-office@ami.acs.org

Reviewer(s)' Comments to Author:

Reviewer: 1

Recommendation: Not appropriate for ACS Applied Materials & Interfaces.

Comments:
In this manuscript, the authors explored that a nanocrystalline (NC) formulation of ABZ to be delivered intradermally using dissolving microneedles (DMNs), so as to improve the solubility and avoid first-pass metabolism of ABZ. The overall study is relatively comprehensive. However, the manuscript need to be further concise. In addition, the manuscript suffers from a number of major weaknesses, and certain aspects need further clarification and revisions. Therefore, the manuscript is not appropriate for ACS Applied Materials & Interfaces.

1. The title of the article is too long and inappropriate. The title should fully express the content of the paper with the minimum number of words.
2. The abstract is too long and needs to be further refinement. In addition, the abstract includes incomplete sentences. For instance, the sentence “affecting both humansand animals••••••”.
3. “CE has been considered as a neglected tropical disease (NTD) by The World Health Organization (WHO), and it has been estimated that around 1-3 million disability cases have been reported as a result of this disease per annum” and “the formulation of nanocrystals (NCs) is one the most attractive and has been widely used due to its flexibility, scalability and high drug loading efficiency”. The references or evidences is missing.
4. In the “Investigation of in vitro release” section, the addition of Tween 80 in the release medium is confusing. In addition, the equation of drug release (%) is missing.
5.In Figure 3, statistical analysis should be added.
6.The authors state that the smallest particle sizes were obtained in the use of P127 as stabilizer and the NCs prepared from P127 with a concentration of 1% w/v and 4 h milling processing time, possessing 418 ± 52 nm particle size. However, the particle size of 418 ± 52 nm is still relatively large, and small particle sizes are easier to absorb. In addition, the data indicate that as the concentration of the stabilizer increases, the formation time and the particle size of the NCs decreases. So why not study the concentrations over 2% w/v of stabilizer to obtain a smaller particle size of NCs.
7. In Figure 4A and 4B, the scale is too large. In addition, the scale of the coarse ABZ´s SEM micrograph should be the same as ABZ-NCs in order to accurately compare the size.
8. The authors state that there was no interaction between ABZ and excipient used in the NCs formulation by FTIR spectra. However, hydrophobic interactions and van der Waals' forces cannot be detected by FTIR spectra.
9. In the “Ex vivo dermatokinetic studies” section, are the needle-free patches suitable for use as a control? Why choose the porcine skin for the ex vivo dermatokinetic test, and the rats selected for the in vivo experiments?
10. As the author described, intradermal delivery was considered as the most suitable option to deliver ABZ because this route could potentially circumvent the first-pass metabolism in the liver, avoiding the metabolism of ABZ. However, after ABZ-NCs administration delivered by DMNs, the Cmax values were 0.32 ± 0.07 μg/mL for ABZ-SX, with AUC0-72 values of 16.51 ± 3.62 h.μg/mL.
11. There is no data showing that the ABZ-NCs administration delivered by DMNs are non-irritating on the skin.

Additional Questions:
Is this paper in the top 20% of manuscripts in the field?: No

If this paper is not in the top 20% of manuscripts in the field: It could be improved to be in the top 20% with further work.

Is it appealing to a broad audience?: No

Does the manuscript give a complete description of the procedures that could be reproduced by others in the field?: Yes

Are the literature references appropriate and up to date?: Yes

Provides significant insight into or the development of an important application: Fair

Work is original and significant: Fair

Conclusions adequately supported by data: Good

Clarity of presentation: Good

Potential for impact in materials science and engineering: Fair

Reviewer: 2

Recommendation: Publish as is; no revisions needed.

Comments:
The manuscript describes the preparation and evaluation (in vitro and in vivo) of a nanocrystalline (NC) formulation of albendazole to be delivered intradermally using dissolving microneedles (DMNs). The

combinatorial approach of NCs and DMNs for the intradermal administration of albendazol has also compared with an oral administration of the drug (either as coarse suspension or in the form of NC). The manuscript is clearly written and the results are well presented and discussed. From my point of view, the manuscript may be accepted for publication. In any case, I would recommend improving the differences between treatments in Figure 7 and Figure 11. Thus, in Figure 7/Figure 11, the lines identifying the different formulations are not clear enough and it is not easy to distinguish the different treatments.

Additional Questions:
Is this paper in the top 20% of manuscripts in the field?: Yes

If this paper is not in the top 20% of manuscripts in the field:

Is it appealing to a broad audience?: Yes

Does the manuscript give a complete description of the procedures that could be reproduced by others in the field?: Yes

Are the literature references appropriate and up to date?: Yes

Provides significant insight into or the development of an important application: Good

Work is original and significant: Good

Conclusions adequately supported by data: Good

Clarity of presentation: Good

Potential for impact in materials science and engineering: Good

Reviewer: 3

Recommendation: Publish after minor revisions noted.

Comments:
Manuscript ID: am-2021-111796
Manuscript title: Albendazole nanocrystal-based dissolving microneedles: A promising approach for intradermal delivery with improved pharmacokinetic performance for enhanced treatment of cystic echinococcosis
Authors: Andi Dian Permana, Alejandro J. Paredes, Fabiana Volpe-Zanutto, Muh. Nur Amir, Ismail Ismail, Muh. Akbar Bahar, Sumarheni, Santiago D. Palma, Ryan F. Donnelly
Overview and general recommendation:
The study aimed to improve albendazole (ABZ) solubility using a nanocrystalline (NC) approach by milling in an ultra-small-scale device and avoiding first-pass metabolism. Then the NCs were incorporated into dissolving microneedles (DMNs) using the combination of poly(vinylpyrrolidone) and poly (vinyl alcohol) formed sharp needles with sufficient mechanical strength and insertion properties
The introduction provides sufficient background and includes to some extent the relevant references. The research design is appropriate, and the methods are adequately described. The results are clearly presented but need more discussion. The conclusions are adequately supported by the data presented. The study integrates knowledge of a material into an important application. The manuscript is likely to be of interest to a reasonable number of scientists working in the field of applied materials and interfaces. However, several issues need to be addressed before this manuscript can be deemed publishable.
1. Page 6, line 135: the authors should mention the full name of Tween 80.
2. What are the specifications of ultra-small-system assembly used in the preparation of NCs?
3. What is the source of silicone moulds that were employed to fabricate the two-layered DMNs?
4. On page 15, line 321: TEA stands for what? Please mention.
5. In figures 4 and 5: correct the typo mistake of the word physical.
6. SEM is more enough for morphology observation of two-layered DMNs than the light microscope.
7. In some sentences, the authors mentioned needles after the abbreviation DMN which is not correct. Please revise.

Regarding the novelty of the article, recently, many publications reported the combination of nanocrystals and microneedles techniques. Furthermore, similar papers were already published in other journals [1–5].

See below key references.
1. Liu, T.; Yu, X.; Yin, H.; Möschwitzer, J.P. Advanced modification of drug nanocrystals by using novel fabrication and downstream approaches for tailor-made drug delivery. Drug Deliv. 2019, 26, 1092–1103, doi:10.1080/10717544.2019.1682721.
2. Pireddu, R.; Schlich, M.; Marceddu, S.; Valenti, D.; Pini, E.; Fadda, A.M.; Lai, F.; Sinico, C. Nanosuspensions and microneedles roller as a combined approach to enhance diclofenac topical bioavailability. Pharmaceutics 2020, 12, 1–14, doi:10.3390/pharmaceutics12121140.
3. Permana, A.D.; Paredes, A.J.; Volpe-Zanutto, F.; Anjani, Q.K.; Utomo, E.; Donnelly, R.F. Dissolving microneedle-mediated dermal delivery of itraconazole nanocrystals for improved treatment of cutaneous candidiasis. Eur. J. Pharm. Biopharm. 2020, 154, 50–61, doi:10.1016/j.ejpb.2020.06.025.
4. Tekko, I.A.; Permana, A.D.; Vora, L.; Hatahet, T.; McCarthy, H.O.; Donnelly, R.F. Localised and sustained intradermal delivery of methotrexate using nanocrystal-loaded microneedle arrays: Potential for enhanced treatment of psoriasis. Eur. J. Pharm. Sci. 2020, 152, 105469, doi:10.1016/j.ejps.2020.105469.
5. Mc Crudden, M.T.C.; Larrañeta, E.; Clark, A.; Jarrahian, C.; Rein-Weston, A.; Lachau-Durand, S.; Niemeijer, N.; Williams, P.; Haeck, C.; McCarthy, H.O.; et al. Design, formulation and evaluation of novel dissolving microarray patches containing a long-acting rilpivirine nanosuspension. J. Control. Release 2018, 292, 119–129, doi:10.1016/j.jconrel.2018.11.002.

Additional Questions:
Is this paper in the top 20% of manuscripts in the field?: Yes

If this paper is not in the top 20% of manuscripts in the field:

Is it appealing to a broad audience?: Yes

Does the manuscript give a complete description of the procedures that could be reproduced by others in the field?: Yes

Are the literature references appropriate and up to date?: Yes

Provides significant insight into or the development of an important application: Good

Work is original and significant: Good

Conclusions adequately supported by data: Good

Clarity of presentation: Fair

Potential for impact in materials science and engineering: Fair

---

FOR ASSISTANCE WITH YOUR MANUSCRIPT SUBMISSION PLEASE CONTACT:
ACS Publications Customer Services & Information (CSI)
Email: support@services.acs.org
Phone: 202-872-4357
Toll-Free Phone: 800-227-9919 (USA/Canada only)

Thank you.

Comments.pdf
66K

BUKTI SUBMIT HASIL REVIEW

Universitas Hasanuddin

Andi Dian Permana <andi.dian.permana@farmasi.unhas.ac.id>

ACS Applied Materials & Interfaces - Manuscript ID am-2021-111796.R1

1 message

ACS Applied Materials & Interfaces <onbehalfof@manuscriptcentral.com> Sat, Jul 10, 2021 at 12:11 AM

Reply-To: support@services.acs.org
To: r.donnelly@qub.ac.uk
Cc: andi.dian.permana@farmasi.unhas.ac.id, a.paredes@qub.ac.uk, f.volpezanutto@qub.ac.uk, nuramir@unhas.ac.id, ismail@unhas.ac.id, akbarbahar@unhas.ac.id, sumarheni@unhas.ac.id, sdpalma@unc.edu.ar, r.donnelly@qub.ac.uk

09-Jul-2021

Journal: ACS Applied Materials & Interfaces
Manuscript ID: am-2021-111796.R1
Title: "Albendazole nanocrystal-based dissolving microneedles with improved pharmacokinetic performance for enhanced treatment of cystic echinococcosis"
Authors: Permana, Andi Dian; Paredes, Alejandro; Zanutto, Fabiana Volpe; Amir, Muh. Nur; Ismail, Ismail; Bahar, Muh. Akbar; Sumarheni, Sumarheni; Palma, Santiago Daniel; Donnelly, Ryan F.
Manuscript Status: Submitted

Dear Dr. Donnelly:

Your manuscript has been successfully submitted to ACS Applied Materials & Interfaces.

Please reference the above manuscript ID in all future correspondence or when calling the office for questions. If there are any changes in your contact information, please log in to ACS Paragon Plus with your ACS ID at http://paragonplus.acs.org/login and select "Edit Your Profile" to update that information.

You can view the status of your manuscript by checking your "Authoring Activity" tab on ACS Paragon Plus after logging in to http://paragonplus.acs.org/login.

ACS Authoring Services

Did you know that ACS provides authoring services to help scientists prepare their manuscripts and communicate their research more effectively? Trained chemists with field-specific expertise are available to edit your manuscript for grammar, spelling, and other language errors, and our figure services can help you increase the visual impact of your research.

Visit https://authoringservices.acs.org to see how we can help you! Please note that the use of these services does not guarantee that your manuscript will be accepted for publication.

Thank you for submitting your manuscript to ACS Applied Materials & Interfaces.

Sincerely,

Dr. Kirk Schanze

ACS Applied Materials & Interfaces

Thank you.

Manuscript ID: am-2021-111796.R1

Title: "Albendazole nanocrystal-based dissolving microneedles with improved pharmacokinetic performance for enhanced treatment of cystic echinococcosis

Authors: Andi Dian Permana, Alejandro J. Paredes, Fabiana Volpe-Zanutto, Muh. Nur Amir, Ismail Ismail, Muh. Akbar Bahar, Sumarheni, Santiago D. Palma, Ryan F. Donnelly

Response to Editor

1) Please respond via email to the following questions so that we may determine how to proceed:

- all authors must have complete first names (not initials or abbreviated names) in the online submission form and the manuscript title page

Response:

We have corrected this in the revised manuscript

- if author Sumarheni uses only one name please confirm this. Does this author have an ORCID ID?

Response:

Sumarheni only use one name as shown in the manuscript. An ORCIS ID for this author is not provided.

- author Santiago Daniel Palma uses a full middle name in the electronic submission form but only the initial D. on the title page. What name does this author use for publication?

Response:

We have corrected this in the revised manuscript.

2) Manuscript file

- your title must be in title case

- Figure 5(a), second line, Physical, not Physicial

Response:

We have corrected this in the revised manuscript.

Albendazole nanocrystal-based dissolving microneedles with improved pharmacokinetic performance for enhanced treatment of cystic echinococcosis

Andi Dian Permana[1], *Alejandro J. Paredes*[2], *Fabiana Volpe-Zanutto*[2,3], *Muh. Nur Amir*[4], *Ismail Ismail*[5], *Muh. Akbar Bahar*[4], *Sumarheni*[6], *Santiago D. Palma*[7], *Ryan F. Donnelly*[2*]

1. Department of Pharmaceutics, Faculty of Pharmacy, Hasanuddin University, Makassar 90245, Indonesia
2. School of Pharmacy, Queen's University Belfast, Medical Biology Centre, 97 Lisburn Road, Belfast. BT9 7BL, UK
3. Faculty of Pharmaceutical Sciences, R. Cândido Portinari, 200 - Cidade Universitária, Campinas - SP, 13083-871, University of Campinas, Brazil
4. Department of Pharmacology and Toxicology, Faculty of Pharmacy, Universitas Hasanuddin, Makassar 90245
5. Department of Phytochemistry, Faculty of Pharmacy, Universitas Hasanuddin, Makassar 90245, Indonesia
6. Department of Clinical Pharmacy, Faculty of Pharmacy, Universitas Hasanuddin, Makassar 90245, Indonesia
7. Unidad de Investigación y Desarrollo en Tecnología Farmacéutica (UNITEFA), CONICET and Departamento de Ciencias Farmacéuticas, Facultad de Ciencias Químicas, Universidad Nacional de Córdoba, Argentina. Haya de la Torre y Medina Allende, X5000XHUA, Córdoba, Argentina.

*Correspondence should be addressed to Professor Ryan F. Donnelly **(**School of Pharmacy, Queen's University Belfast). Email: r.donnelly@qub.ac.uk

ABSTRACT

Cystic echinococcosis (CE) is a zoonosis caused by *Echinococcus* spp., affecting both humans and animals' lives. Current treatment of CE by oral administration of albendazole (ABZ) is hampered by several limitations. The poor aqueous solubility and the rapid metabolism of ABZ in the liver are the main issues, leading to lack of efficacy of the treatment. In the present study, we developed a nanocrystalline (NC) formulation of ABZ to be delivered intradermally using dissolving microneedles (DMNs). The NC formulation was developed using milling in an ultra-small-scale device. Following several screenings, Pluronic® F127 was selected as a suitable stabilizer, producing NCs with around 400 nm in size with narrow particle distribution. The crystallinity of ABZ was maintained as observed by DSC and XRD analysis. The NC approach was able to improve the dissolution percentage of ABZ by approximately 3-fold. Furthermore, the incorporation of NCs into DMNs using the combination of poly(vinylpyrrolidone) and poly (vinyl alcohol) formed sharp needles with sufficient mechanical strength and insertion properties. Dermatokinetic studies revealed that >25% of ABZ was localized in the dermis of excised neonatal porcine skin up to 48 h after DMN administration. In *in vivo* pharmacokinetic studies, the AUC and relative bioavailability values of ABZ delivered by NC-loaded DMNs were found to be significantly higher than those obtained after oral administration of coarse suspension of ABZ or ABZ-NCs, as well as DMNs delivering coarse ABZ as indicated by the relative bioavailability values of > 100%. Therefore, the combination approach developed in this study could maintain the systemic circulation of ABZ which could be possibly caused by avoiding the first-pass metabolism in the liver. This could be beneficial to improve the efficacy of ABZ in CE treatment.

KEYWORDS: Albendazole, nanocrystals, microneedles, cystic echinococcosis, pharmacokinetics

1. Introduction

Cystic echinococcosis (CE) is a devastating zoonosis which affects both humans and animals. CE is caused by *Echinococcus* spp., commonly *Echinococcus granulosus*.[1,2] After infecting human, *Echinococcus granulosus* enters the systemic circulation and are accumulated in the liver and other organs, forming hydatid cysts.[3] This infectious disease causes a significant public health issue worldwide, including areas of central South America, Asia, and even in Mediterranean countries[4]. Moreover, despite the fact that the infected body produces humoral immune and specific cellular responses, a persistent cohabitation of *Echinococcus granulosus* and has been found to be the main challenge in this disease.[5,6]Additionally, CE has been considered as a neglected tropical disease (NTD) by The World Health Organization (WHO), and it has been estimated that around 1-3 million disability cases have been reported as a result of this disease per annum.[7] Furthermore, around US$3 billion have been spent yearly because of direct and indirect effects of this disease on both human and livestocks.[8]

Presently, there are several choices for the treatment of CE. These include antiparasitic administration, surgical intervention, and percutaneous drainage therapy. The selection of treatments is dependent on the nature of the cysts in each patient.[9] The administration of antiparasitic agents is the first treatment option where doctors are not available. Additionally, this is the only alternative in numerous inoperable circumstances, including cysts in the brain and cysts in patients who are immune-supressed.[10] Currently, the benzimidazole carbamate derivate, albendazole (ABZ), is the most effective drug commonly used for the treatment of CE. However, ABZ has poor aqueous solubility, resulting in low bioavailability when administered orally. This leads to lack efficacy, with only one third of patients suffering from hydatid cysts showing complete remission and 20-40% of patients not responding to ABZ therapy.[11] Consequently, the drug should be taken in high doses (10-15 mg/kg of body weight) and for long periods (3-6 months), leading to liver toxicity, gastrointestinal toxicity and other

side effects.[12–14] In addition, due to its low solubility in aqueous environments, the route of administration options are limited to the oral route.[15,16] Therefore, it is crucial to develop a formulation which can overcome the poor solubility.

Multiple approaches have been explored in order to improve the biopharmaceutical performance of ABZ, including the formulation of solid dispersions[17], oil-in-water emulsions[18], inclusion complexes with cyclodextrines[19], co-grinding with hydrophilic excipients[20], liposomes[21], nanocapsules[22], chitosan microspheres[23], and nanocrystals (NCs)[24–26]. Despite the fact that these efforts have been partially successful in increasing the dissolution rate and *in vivo* absorption of the drug, they were developed for oral administration. When administered orally, ABZ encounters rapid first-pass metabolism in the liver, being transformed into ABZ-sulfoxide (ABZ-SX).[27] Although ABZ and ABZ-SX show antiparasitic activities, ABZ has been reported to possess stronger affinity to parasite tubulins when compared to ABZ-SX, meaning that ABZ has higher activity than ABZ-SX.[28] It has also been reported that the viability of cysts in NMRI mice infected by *Echinococcus granulosus* was lower after the administration of ABZ compared to those with the administration of ABZ-SX.[29] Accordingly, a new delivery approach which can avoid the rapid metabolism of ABZ in the liver may enhance the efficacy of ABZ in the treatment of CE.

Transdermal delivery systems are one of the most favorable methods to improve the delivery of numerous drugs and are able to avoid hepatic first-pass metabolism,[27,30] Amongst various delivery approaches, dissolving microneedles (DMNs) have shown numerous advantages compared to other strategies,[31] since they by-pass the skin's *stratum corneum*.[32] DMNs comprises of needles <1 mm in height. Importantly, the application in human volunteers did not result in any pain, providing compliant administration.[33] Furthermore, post-application, DMNs administration does not produce any biohazardous waste.[27,34]

Among the strategies used to enhance the dissolution rate of poorly soluble drugs mentioned above, the formulation of nanocrystals (NCs) is one the most attractive and has been widely used due to its flexibility, scalability and high drug loading efficiency.[35] This approach has resulted in more than 20 approved products in the market globally.[36] NCs are described as nanometer-sized drug particles without matrix substances in crystalline from, consisted of up to 90% hydrophobic drug which are generally stabilized by surfactants.[37] NCs enhance the saturation solubility and the rate of dissolution of hydrophobic drugs by reducing the particle size and, thus enlarging their surface area.[38] This approach has been successfully applied in the formulation of several hydrophobic drugs, including curcumin,[39] budesonide,[40] and a number of highly hydrophobic antifungal drugs[41–43], displaying that the dissolution rates of the aforementioned drugs were significantly improved. Importantly, the combination of NCs and DMNs technologies has shown promising results in the systemic delivery of poorly soluble drugs for both, local and systemic effects.[44] Considering the significant advantages of DMNs and NCs, the delivery approach combining these systems could be a favorable choice to maintain the systemic availability of ABZ for improved effective therapy of CE.

In the presented study, we develop, for the first time, the combinatorial approach of NCs and DMNs for the intradermal administration of ABZ using to improve its bioavailability. Initially, the NCs were developed using top-down method using an ultra-small-scale media mill. Several characterizations were further performed, including particle size, polydispersity index, physical characteristics and drug release kinetics were further characterized. Subsequently, the NCs were loaded into DMNs and characterizations of mechanical properties were carried out. Moreover, *ex vivo* dermatokinetic studies were also performed to examine the intradermal delivery of this approach. Finally, *in vivo* pharmacokinetic studies of ABZ in NCs after DMN administration in rats were compared to the conventional administration of ABZ in CE therapy.

2. EXPERIMENTAL SECTION

2.1. Materials. Albendazole and albendazole sulfone (purity, ≥98%) of analytical grade were purchased from Alfa Aesar (Lancashire, UK). Albendazole sulfoxide (purity, ≥98%), Polyoxyethylene (20) sorbitan monooleate (Tween®80), poly(vinyl alcohol) (PVA) (9–10 kDa) and PVA (31–50 kDa) were obtained from Sigma-Aldrich (Dorset, UK). Poly(vinylpyrrolidone) PVP (58 kDa) was obtained from Ashland (Kidderminster, UK). Pluronic® F127 (P127) was gifted by BASF SE (Ludwigshafen, Germany). Yttria stabilized zirconia beads of 0.5 mm diameter were obtained from Chemco Advance Material (Suzhou, China). Importantly, other reagents were all obtained from standard commercial suppliers and were analytical grade.

2.2. Fabrication of ABZ-NCs. A media milling technique utilizing an ultra-small-system assembly was applied to prepare ABZ-NCs,[45] with minor changes. The system consisted of small glass vial with volume of 12 mL, two magnetic bars of (12 x 8 mm) and magnetic stirrer, as shown in Figure 1. Initially, 0.25 g of ABZ, 8 g of zirconia beads and 10 ml of stabilizer were put in the glass vial. Afterwards, two magnetic bars were added into the system. Then, the system was locked with an airtight cap. The formulation was stirred for 24 h at 1000 rpm on Magnetic Stirrer (IKA, Staufen, Germany). In order to obtain the optimum time process, samples were taken at predetermined interval times for particle size determinations. Subsequently, to separate the zirconia beads and the magnetic bars, the dispersion obtained was strained using a mesh 200 sieve. In this study, Tween 80, P127 or PVA with the concentrations of 0.5% w/v, 1% w/v and 2% w/v in water were screened as stabilizer.



Figure 1. Schematic representation of NC preparation

2.3. Characterization of ABZ-NCs. Dynamic light scattering (DLS) utilizing a particle size analyzer (NanoBrook Omni®, Brookhaven, New York, USA) was applied in order to determine particle size and polydispersity index of ABZ-NCs. The measurements were done in triplicate. To observe the morphology of ABZ-NCs, scanning electron microscopy (SEM) (TM3030 microscope, Hitachi, Krefeld, Germany) was used. The coarse dispersion of ABZ in water was also observed as comparison.

In order to investigate the chemical interactions of each component in the formulation, a Fourier transform infrared (FTIR) spectrometer (Accutrac FT/IR-4100™ Series, Perkin Elmer, USA) was used. Additionally, the crystallinity of ABZ-NCs was observed using two different methods, namely differential scanning calorimetry evaluation (DSC 2920, TA Instruments, Surrey, UK) and an X-ray diffraction analysis (Rigaku Corporation, Kent, England). Coarse ABZ powder, ABZ-NCs and physical mixture (PM) of the optimized formulation were used for these studies.

2.4. Investigation of *in vitro* release. A dialysis method was used to assess the *in vitro* release of ABZ-NCs in comparison with coarse ABZ.[46] The release study was carried out in

PBS (pH 7.4) containing 1% w/v of Tween 80. Briefly, ABZ (10 mg) and ABZ-NCs (containing 10 mg of ABZ) were placed into dialysis membrane. Membrane used in this study possessed 12,000–14,000 molecular weight cut-off (MWCO) (Spectra-Por®, Spectrum Medical Industries, Los Angeles, CA, USA). Initially, the membrane was then placed into 100 mL of dissolution media. The study was performed for 24 hours and at 37˚C at 100 rpm. At predetermined times, 1 mL of release medium was taken, and replaced with 1 mL of fresh medium. Finally, the amount of ABZ released was analyzed using HPLC. The drug release percentages were then calculated using Equation 1.

$$\text{The drug release percentage} = \frac{ABZ\ detected\ in\ the\ release\ study}{initial\ amount\ of\ ABZ}\ x\ 100\% \qquad \text{Equation 1}$$

The drug release profile of ABZ from ABZ-NCs was fitted to various mathematic models, namely zero order, first order, Higuchi, Korsmeyer-Peppas and Hixson-Crowell.[33,41] DDsolver (China Pharmaceutical University, Nanjing, China) was used to determine the parameters of each model.

2.5. Fabrication of two-layered DMNs. In order to incorporate the NCs into DMNs, initially, the NCs obtained were centrifuged for 30 min at 14,000 rpm using a centrifugation system (Sigma® 1–14 micro-centrifuge, SciQuip Ltd., Shropshire, UK). This step was repeated three times in order to wash the NCs using distilled water, generating washed NCs pellets. The DMNs matrix used was an aqueous blend of the mixture of 25% w/w of PVP (58 kDa) and 15% w/w of PVA (31-50 kDa). As template, silicone moulds were employed to fabricate the two-layered DMNs. The moulds were prepared utilizing the transparent LSR9–9508- 30 silicone elastomer mix (part A: part B 1:1 w/w). The moulds possessed 16 x 16 needles with pyramidal shapes. The height of each needle was 850 µm with 250 µm base colum and 600 µm pyramidal tip. The base and interspacing between each needle were 300 µm.[47] To develop the DMN formulation, the first layer of DMNs containing ABZ-NCs and DMNs matrix was

prepared in five different NC concentrations, namely 10% ABZ-NCs (Formulation A), 20% ABZ-NCs (Formulation B), 30% ABZ-NCs (Formulation C) and 40% ABZ-NCs (Formulation D). The second layer of the formulation was the polymeric solution containing PVP (90 kDa) 30% w/w. To enhance the elasticity, the second layer solution was mixed with glycerol 1.5% w/w. Figure 2 shows the schematic representation of two-layered DMN preparation. Following the mixing process, casting process of the first layer was conducted by pouring the formulation onto the DMN moulds. Afterwards, the moulds were put in a positive pressure chamber for 2 min and pressure of 5 bar was applied. Then, the excess formulation was removed from the top of the moulds. To facilitate the attachment of the second layer, a silicone ring was fixed to the MN moulds.[48,49] Then, the second layer formulation (850 µL) was poured on top of first layer, secured by the holder ring. The moulds were then centrifuged for 15 min at 3500 rpm. The drying process was divided into two steps. For the first 24 hours, the formulations were dried at room temperature. Finally, the formulations were dried at 37˚C for 12 hours.



Figure 2. Schematic representation of two-layered DMN preparation

2.6. Morphology observation of two-layered DMNs. The morphologies of DMNs containing ABZ-NCs were visualized. Two different methods were used, namely light microscopy using A Leica EZ4D light microscope (Leica Microscope, Milton Keynes, UK) and scanning electron microscopy using SEM TM3030 (Hitachi, Krefeld, Germany).

2.7. Assessment of mechanical and insertion properties of two-layered DMNs. The mechanical strength of DMNs laden with ABZ-NCs was examined using a TA.XT2 Texture Analyzer (Stable Micro Systems, Haslemere, UK), as reported previously. The force applied was 32 N/array for 30 s.[50] The mechanical strength was presented by the height percentage reduction of DMNs after the compression compared to the height before the compression.

The insertion ability of DMNs in both full-thickness neonatal porcine skin and an established skin-simulant artificial membrane, Parafilm®M was examined utilizing an optical coherence tomography (OCT) microscope (Michelson Diagnostics Ltd., Kent, UK), as published ealier.[32,50,51] The study was carried out by inserting the DMNs using Texture Analyzer with the force of 32 N/array for 30 s into eight layers of Parafilm®M. The number of holes created in each layer of Parafilm®M following the insertion of DMNs was counted. Furthermore, the visualizations of DMNs insertion and penetration depth into full-thickness neonatal porcine skin and Parafilm®M were carried out using ImageJ® (National Institute of Health, Bethesda, MD, USA).

2.8. Quantification of drug content localized in the needle tips of DMN. To determine the quantity of ABZ in the needle tips of DMN, initially, a scalpel was used to carefully detache the first layer of DMNs. The collected part was further solubilized in 10 mL methanol. In order to completely dissolve ABZ, the mixture was placed for 1 h in a bath sonicator and centrifuged at 14,000 rpm for 15 min. The amount of ABZ in the supernatant was analyzed using HPLC.

2.9. Determination of particle size of ABZ-NCs in DMN formulations. To evaluate the effect of DMN formulations on the size of ABZ-NCs, initially, the DMNs laden with ABZ-NCs were completely dispersed in distilled water. Following this step, the particle size and PDI

of NCs and were determined using the similar technique and those values were equated to the initial particle size and PDI.

2.10. Microneedles dissolution study. The *in situ* skin dissolution time of DMNs was studied as per a method reported previously.[33] Briefly, the DMNs were inserted into the center of the skin section using manual pressure. A cylindrical stainless-steel weight (5.0 g) was positioned on top of the DMNs during the dissolution study. At defined time points, DMNs were detached from the skin and the shape of DMNs was viewed utilizing the light microscope.

2.11. *Ex vivo* dermatokinetic assessments. Evaluation of *ex vivo* dermatokinetic of ABZ from DMNs-NCs formulation were conducted in excised full-thickness porcine skin in Franz cell diffusion cells using a technique described in our previous publications.[27,32] Initially, the DMNs were inserted manually into the skin and the skin was fixed into Franz cell diffusions using cyanoacrylate glue. In this study, PBS (pH 7.4) and 1% w/v of Tween 80 were used as receptor medium. The cylindrical stainless-steel weight (5 g) was put on top of the DMNs. The experiment was carried out at 600 rpm at 37 ± 1°C. The skin samples were taken at defined interval times, separated from DMNs and washed with PBS. Then, the skin was pierced using a biopsy punch with diameter of 5 mm (Stiefel, Middlesex, UK). To separate the epidermis from the dermis layers, the skin samples were heated in a water bath for 2–3 min at 60°C. The epidermis was carefully separated from the dermis using forceps. Following this step, ABZ was extracted from the skin by adding 1 mL methanol to the skin sections and the mixture was then homogenized using Tissue Lyser LT (Qiagen, Ltd., Manchester, UK) at 50 Hz for 10 min. The determination of ABZ was carried out using HPLC. A curve comprising drug concentration versus time of application was made and PKSolver (China Pharmaceutical University, Nanjing, China)[52] was applied to calculate the dermatokinetic profiles using a one-compartment open model. The maximum drug concentration (C_{max}), the time of maximum

concentration (t_{max}), the area under the curve from time zero (t = 0) to the last experimental time point (t = 24 h) (AUC), the mean half-life ($t_{1/2}$) and the mean residence time (MRT) were all calculated. The dermatokinetic assessments of needle-free patches loaded with ABZ NCs (ABZ-NCs) were also carried out as control.

The distribution and deposition study of ABZ in different skin depths were further evaluated. Briefly, skin samples after the administration of DMNs in different time points, namely 1 h, dermis t_{max} from the dermatokinetic study and 24 h were detached from Franz cell diffusion cells. Following this step, a silicone mould was filled with the skin samples, mixed with optimal cutting temperature (OCT) media media (Tissue TEK®) and frozen using liquid nitrogen. Afterwards, the sectioned skin samples with thickness of 50 μm were obtained using a Leica CM1900 Cryostat (Leica Microsystems, Nussloch, Germany). Afterwards, this step was carried out until all samples was completely cut. Five consecutive skin samples (total thickness of approximately 2.5 mm) were collected into the same microtube. Subsequently, ABZ was extracted from skin samples in 1 mL methanol, vortexed for 15 min and centrifuged at 14,000× *g* for 15 min. Finally, the supernatant was taken and analyzed using HPLC.

2.12 In vivo study

2.12.1. Assessment of the pharmacokinetics of ABZ, ABZ-SX and ABZ-SN in Wistar rat's plasma. The *in vivo* pharmacokinetic assessment was carried out to evaluate the delivery of ABZ from DMNs-NCs in healthy male Wistar rats weighing 208.17 ± 13.31 g. This study was conducted in compliance with the Health Ethical Committee at the Faculty of Medicine, Hasanuddin University, Indonesia. One week before the *in vivo* experiment, the rats were adapted to the laboratory conditions. During the adaptation and the experiment periods, food and water were given *ad libitum*. The animals were divided into four cohorts (*n* = 5 per cohort) and treated as follows: Group A received 2 x DMNs containing ABZ-NCs; Group B received

2 x DMNs containing coarse ABZ; Group C received 1 mL ABZ-NCs orally and Group D received 1 mL ABZ coarse suspension. All cohorts received a dose which was equal to 15 mg/kg of ABZ.

For the groups receiving DMNs, the rats' hair on the back region was shaved using an electric clipper, followed by the use of hair removal cream (Veet®). DMNs were initially attached to Microfoam® tape and administered using finger pressure for 30 s onto the shaved area of the rats. Following this step, the DMNs were secured using Tegaderm™ (3 M, St Paul, Minnesota, USA). Then, Micropore™ tape (3 M UK Plc, Bracknell, Berkshire, UK) was applied on top of Tegaderm™. Blood samples of the rats from all cohorts were taken at 0.5, 1, 2, 4, 6, 12, 24, 48 and 72 h. The blood collected was placed into an Eppendorf tube containing 3.8% w/v of sodium citrate. To obtain the plasma samples, tubes were centrifuged for 10 min at 4°C at 3000 x g. Prior to analysis, the plasma samples were kept at -20°C.

2.12.2 Sample preparation and analyte extraction. To extract ABZ from plasma samples after the *in vivo* pharmacokinetic studies, a simple one-step protein precipitation technique utilizing methanol was applied. First of all, in an Eppendorf tube, 500 µL of methanol was added to 100 µL plasma. The mixture was vortexed for 10 min and centrifuged at 14,000 x g at 4°C for 15 min. The supernatant was collected and dried in a fume hood for 3 h in a glass vial. Afterwards, 100 µL of the mobile phase was added into the residue. The mixture was vortexed for 10 min. The supernatant was obtained by centrifugation at 14,000 x g for 15 min. The samples were analyzed using HPLC. In addition to ABZ, ABZ-SX and ABZ-SN as the metabolites of ABZ, were also analyzed .

2.12.3 Calculation of pharmacokinetic parameters. The of drug concentration in plasma versus sampling time was constructed. The pharmacokinetic profiles were analyzed

using a non-compartmental model. The maximum drug concentration (C_{max}), the time of maximum concentration (t_{max}), the area under curve from time zero (t = 0) to the last experimental time point (t = 24 h) (AUC), the mean half-life ($t_{1/2}$) and the mean residence time (MRT) were calculated using PK Solver [52].

The relative plasma bioavailability (F) of ABZ following intradermal administration of NCs delivered from DMNs, in comparison with oral administration, was estimated using Equation 2.

$$F = \frac{AUC_{MN}\ x\ dose_{oral}}{AUC_{oral}\ x\ dose_{MN}}\ x\ 100\% \qquad \text{Equation 2}$$

Where, AUC_{MN} is the AUC of plasma from DMNs administration, AUC_{oral} is the AUC of plasma oral administration of ABZ.

2.13. The chromatographic condition for ABZ analysis. Quantification of ABZ in in vitro studies was performed using HPLC (Agilent Technologies 1220 Infinity UK Ltd, Stockport, UK). The stationary phase used in this study was Phenomenex® Luna C_{18} (ODS1) column with internal diameter of 150 mm x 4.6 mm and particle size of 5 µm. The mobile phase used was the mixture of 25 mM sodium dihydrogen phosphate buffer containing 0.1% v/v triethylamine (TEA) (pH 3) and methanol with a ratio of 75:25 v/v. The chromatographic conditions were flow rate of 1 mL/min and injection volume of 25 µL. The analyses were carried out at room temperature and all samples were detected at 290 nm. The analytical method was validated according to the International Conference on Harmonization (ICH) 2005. The limit of detection (LoD) and the limit of quantification (LoQ) values of ABZ were 0.002 µg/mL and 0.03 µg/mL, respectively.

In *in vivo* experiments, the analyses of ABZ, ABZ-SX and ABZ-SN were carried out using HPLC (Shimadzu Prominence, Shimadzu, Kyoto, Japan). The analyses were conducted utilising an Xselect CSH™ C18 column with 3.0 x 150 mm internal diameter and 3.5 µm particle size. The mobile phase used was the mixture of 0.1% v/v of trifluoracetic acid in water and methanol with a ratio of 75:25 v/v. The chromatographic conditions were; flow rate of 1 mL/min, UV detection at 290 nm and injection volume of 25 µL. The analyses were again carried out at room temperature. The bioanalytical assay was validated according to the International Conference on Harmonization (ICH) 2005. The limit of detection (LoD) values were 0.003 µg/mL, 0.002 µg/mL and 0.003 µg/mL; and the limit of quantification (LoQ) values were 0.02 µg/mL, 0.01 µg/mL and 0.02 µg/mL for ABZ, ABZ-SX and ABZ-SN, respectively.

2.14. Statistical analysis. Statistical analysis was carried out using GraphPad Prism® version 6 (GraphPad Software, San Diego, California, USA). All results were presented as means ± standard deviation (SD). An unpaired t-test was applied to analyze the results from two cohorts. To compare more than two cohorts, one-way ANOVA was applied. Data was considered significantly different when p values < 0.05.

3. Results and Discussion

3.1. Fabrication and characterizations of ABZ-NCs. In the present work, NCs-based formulations were developed to overcome the poor aqueous solubility of ABZ. Specifically, the top down technique using modified media milling was selected. This method forms NCs according to mechanical abrasion to transform large crystalline particles into nanosized particles.[53] Compared to the bottom up technique, this method has been reported to be more likely to maintain the crystalline form of the particles.[54] Several stabilizers were screened,

including Tween 80, PVA and P127, with different concentrations. The graphs presenting the particle size and PDI values in the screening proses are depicted in Figure 3.

Tween® 80 produced particles possessing sizes in nanometer scales at the stabilizer concentrations of 0.5% w/v and 1% w/v after 12 h. Meanwhile, after 10 h, the NCs were formed when 2% w/v of stabilizer was used. The particle sizes of NCs were found to be 732 ± 87 nm for 0.5% w/v, 683 ± 76 nm for 1% w/v and 489 ± 38 nm for 2% w/v after 24 h. The PDI values obtained were more than 0.3, showing the wide distribution of the NCs. This could potentially result in physical instability of NCs due to the Ostwald ripening phenomenon.[55] Nevertheless, this phenomenon could only occur in the liquid environment. This can be circumvented by the removal of the solvent and changing the NCs dispersion into a solid state.[56] Accordingly, because DMNs are solid in their forms, the combination of NCs and DMNs could be potentially beneficial to avoid this instability. Moreover, the utilization of PVA as stabilizer could generate NCs after 10 h milling time for the concentration of 0.5% w/v and 8 h milling time for the concentrations of 1% w/v and 2% w/v. The PDI values were found to be more than 0.3. Specifically, the particle sizes obtained after 24 h were observed to be 626 ± 65 nm for 0.5% w/v the stabilizer concentrations, 372 ± 32 nm 1% w/v the stabilizer concentrations and 368 ± 29 nm 2% w/v the stabilizer concentrations, respectively. The smallest particle sizes were obtained in the use of P127 as stabilizer. The NCs were formed after shorter milling time, 4 h for the stabilizer concentration of 0.5% w/v; 3 h for the stabilizer concentrations of 1% w/v and 2% w/v. After 24 h, the particle sizes of NCs were observed to be 621 ± 74 nm, 369 ± 45 nm and 356 ± 39 nm for the concentrations of 0.5% w/v, 1% w/v and 2% w/v. Importantly, the PDI values obtained were below 0.3, indicating narrow particle distributions.[24] The NCs stabilization prepared from P127 can be explained by the presence of hydrophobic poly (propylene oxide) (PPO) and hydrophilic poly (ethylene oxide) (PEO) chains.[32] The PPO chains of poloxamer facilitate the stabilizer to adsorb onto the hydrophobic surface of the drug

crystals.[57] Furthermore, aggregation is inhibited by the extension of PEO chains into the aqueous phase, offering steric stabilization.[58] In this study, we found that, in comparison with the particle sizes with milling times of 4 h, the particle sizes after longer milling times, including 24 h did not considerably change ($p > 0.05$). Additionally, the particle sizes obtained by the use of 1% w/v P127 were not statistically different in comparison with those obtained from 2% w/v P127. Accordingly, with the aim to minimize the production time and the use of stabilizer, the NCs prepared from P127 with a concentration of 1% w/v and 4 h milling processing time, possessing 418 ± 52 nm particle size and 0.29 ± 0.03 PDI were chosen for the further steps.



Figure 3. The particle size (1) and PDI (2) values of ABZ-NCs formulated using Tween 80 (**A**), PVA (**B**) and P127 (**C**) at 0.5, 1 and 2 % w/v (means ± SD, $n = 3$, * $p < 0.05$)

In the NCs characterizations, several methods were applied. First, the morphology of ABZ-NCs was observed using SEM. The SEM micrographs of ABZ-NCs and coarse ABZ are exhibited in Figure 4. It was observed that the size of ABZ-NCs in SEM analysis was found to be similar with the size obtained in DLS measurement, which was around 300 nm.

Furthermore, the interactions between ABZ and excipients were also evaluated. The FTIR spectra of ABZ, physical mixture of NC formulation and ABZ-NCs are presented in Figure 4. The spectrum of FTIR of ABZ exhibited several absorptions, due to the presence of several functional groups. The signal identified at 1193 cm^{-1} could be due to the presence of the C-O-C bond. The signals observed at 1635 cm^{-1} and 1572 cm^{-1} were attributed to the N-H out of the plane bending of ABZ structure. The presence of carbonyl groups was identified at 1709 cm^{-1}. In addition, the sharp peaks found at 2935 cm^{-1} and 2878 cm^{-1} were due to the C-H stretching. Finally, the peaks at 3331 cm^{-1} and 2705 cm^{-1} were detected, which might be due to the presence of N-H stretching and the hydrogen bond between imidazole-NH and carbamate carbonyl, respectively. Importantly, these peaks were also observed in the physical mixture and ABZ-NCs formulation. Therefore, it could be concluded that there was no formation of a new chemical bond between ABZ and excipient used in the NCs formulation. However, it is important to note that hydrophobic and van der Waals interactions cannot be observed by FTIR.

To further investigate the crystallinity of ABZ after NCs preparation, DSC and XRD analyses were then performed. The DSC thermogram of ABZ, physical mixture of NC formulation and ABZ-NCs are depicted in Figure 5. It was found that ABZ had a sharp endothermic peak representing the melting point of ABZ at 193°C. Additionally, the melting point peak was followed by a recrystallization of the melt at 207°C. These peaks were also observed in the physical mixture and ABZ-NCs formulation. The presence of the melting point peak indicated the crystal form of ABZ. The crystallinity was also observed in XRD

examination, displaying sharp signals at 2θ values of 6.63, 11.73, 16.72, 19.82 and 27.92 in ABZ, physical mixture and ABZ-NCs, respectively (Figure 4). Accordingly, the formulation of NCs using media milling allowed maintenance the crystallinity of ABZ.



Figure 4. SEM images of coarse ABZ (**A**) and ABZ-NCs (**B**) at a magnification power of 30000x (The black scale bar shows a length of 1 µm). FTIR spectra of ABZ, physical mixture and ABZ-NCs (**C**). X-ray diffractogram of ABZ, physical mixture and ABZ-NCs (**D**).

3.2. Investigation of *in vitro* release. Following its formulation into NCs, the *in vitro* release of ABZ was compared to the release of pure ABZ, as shown in Figure 5. After 24 h,

only 28.11 ± 4.32% cumulative release was achieved from pure ABZ. On the other hand, the ABZ NCs improved the *in vitro* release of ABZ, showing percentage release of 89.92 ± 11.02% (approximately three times higher than pure ABZ) after 24 h. After statistical analysis, it was found that the release percentage of ABZ from NCs after 24 h was significantly greater (p = 0.017) in comparison to ABZ without NC formulations. The increase in the percentage of cumulative release of ABZ following the NCs formulation is related to the expanded specific surface of ABZ after the particle size reduction, resulting in an enhancement in the dissolution rate.[24,59]



Figure 5. DSC thermogram of ABZ, physical mixture and ABZ-NCs (**A**). *In vitro* release percentages of ABZ from NC formulations compared to the coarse ABZ (means ± SD, n = 3) (**B**).

In an attempt to determine the release mechanism of ABZ from NCs formulation, the release profile was fitted to various kinetic models. The results revealed that the values of correlation coefficient were 0.43 for Zero-order, 0.92 for First-order, 0.56 for Higuchi, 0.81 for

Korsmeyer-Peppas and 0.76 for Hixson-Crowell, respectively. As the selection of the most suitable release model was performed according to the highest correlation coefficient value, the First-order kinetic model was found to be the most appropriate release model. Accordingly, concentration dependent was considered as the release mechanism of ABZ from the NCs formulation.[32,60] Several studies have shown the suitability of this model in describing several NC formulations.[32,41,48]

3.3. Fabrication and morphology observation of two-layered DMNs. As previously discussed, the main aim of this study was to incorporate ABZ-NCs into DMNs. Herein, an aqueous blend containing a specific combination of PVA and PVP was selected. These polymers have been extensively utilized as polymer matrixes for DMN formulations. Based on our previous investigation, the combination of PVA and PVA could produce DMNs with better characteristics when compared to DMNs prepared from PVA alone or PVP alone. This may be explained by the interaction of -OH groups of PVA and C = O groups of PVP, forming hydrogen bonds.[27] A two-layered DMNs approach was selected in this study. This system offers several advantages. It has been reported that the permeation of hydrophobic drugs from DMNs only occurred in the needle parts of DMNs. Therefore, to prevent drug waste in the baseplate of DMNs, the drug was only localized in the needles.[27,61] Moreover, our initial investigation showed that the DMNs containing ABZ-NCs in the whole DMNs exhibited poor mechanical properties. Therefore, it was crucial to formulate the DMN baseplates using a different formulation. In this case, an aqueous blend containing 1.5% w/w glycerol and 30% w/w PVP (360 kDa) was used as a second layer baseplate. In the first layer, several formulations were screened in order to achieve a formulation with high drug loading and adequate mechanical properties. After preparation, all DMNs were observed by a light microscope and a SEM, as shown in Figure 6. All DMNs prepared in this study exhibited

homogenous polymer mixtures with sharp needle tips formed. Thus, all formulations were evaluated for their mechanical and insertion properties.



Figure 6. Light microscope pictures (**A**) of the DMN formulations prepared from 10% ABZ-NCs (Formulation A) (**1**), 20% ABZ-NCs (Formulation B) (**2**), 30% ABZ-NCs (Formulation C) (**3**), 40% ABZ-NCs (Formulation D) (**4**) and 50% ABZ-NCs (Formulation E) (**5**). SEM images (**B**) of the MN formulations containing 10% ABZ-NCs (Formulation A) (**1**), 20% ABZ-NCs (Formulation B) (**2**), 30% ABZ-NCs (Formulation C) (**3**), 40% ABZ-NCs (Formulation D) (**4**) and 50% ABZ-NCs (Formulation E) (**5**).

3.6. Assessment of mechanical and insertion properties of two-layered DMNs. After the fabrication process, the DMNs containing ABZ-NCs were further characterized for their mechanical strength. This property is crucial because DMNs should have an adequate strength to penetrate the skin to deliver their drugs cargo. The strength was evaluated based on needle height reduction percentage following compression with 32 N/DMN array.[62] The mechanical properties presented by the percentage of the height reduction of all DMN formulations are exhibited in Figure 7. The percentages of the height reduction were calculated to be 10.63 ± 2.81%, 11.65 ± 2.19%, 11.97 ± 3.02%, 12.87 ± 3.21% and 19.76 ± 2.65% for Formulation A, Formulation B, Formulation C, Formulation D and Formulation E, respectively. The percentage needle height reductions between Formulation A, Formulation B, Formulation C, Formulation D and Formulation E was not considerably different ($p > 0.05$). Nevertheless, the percentage needle height decreases of the DMNs containing 50% w/w ABZ-NCs (Formulation E) were significantly ($p < 0.05$) higher compared to other formulations, indicating the decrease of mechanical strength of Formulation E. Accordingly, the mechanical properties of DMNs in this study were affected by the drug cargo concentration.



Figure 7. The percentage of height reduction of needles on the DMN arrays prepared from ABZ-NCs (means ± SD, *n* = 3) (**A**). The percentage of holes generated in Parafilm®M layers, applying an insertion force of 32 N/array for DMN formulations fabricated from ABZ-NCs (means ± SD, *n* = 3) (**B**). Illustrative OCT micrographes of Formulation D following insertion into Parafilm®M film (**C**) and full-thickness porcine skin (**D**).

In addition to the mechanical strength, the insertion ability of DMNs weas further evaluated. In this study, Parafilm®M was employed as an established skin-simulant membrane. This artificial membrane has been established to replicate human skin in MN insertion assessment.[62] The results of this evaluation were depicted in Figure 7. Similar to the outcomes from the mechanical characteristics assessment, Formulation A, Formulation B, Formulation C and Formulation D were able to penetrate four layers of Parafilm®M. Considering that the

thickness of each layer was approximately 126 µm, around 54% (504 µm insertion) of the needle tips of DMN of those formulations were inserted into the skin-stimulant membrane. In contrast, only two layers of Parafilm®M were able to be penetrated by Formulation E, a percentage insertion of less than 50%. Accordingly, Formulation E developed in this study possess the lowest mechanical and insertion abilities. Formulation D with the highest drug loading ability (40% w/w) was thus selected for further studies. The selected formulation was then characterized by visualizing visualization using OCT. This technique has been employed to study the insertion profiles of DMN in various studies.[50,63–67] The insertion visualizations were observed in the Parafilm®M and the full-thickness neonatal porcine skin. Figure 7C and tD represent the OCT micrographs illustrating the insertion of Formulation D into the Parafilm®M and the full-thickness neonatal porcine skin. It was found that Formulation D was able to penetrate the Parafilm®M and the full-thickness porcine skin until the depth of 501.59 ± 23.47 µm and 505.29 ± 19.82 µm, respectively. The results obtained in the OCT evaluation were found to be similar to the insertion investigation results observed in the percentages of holes produced in Parafilm®M.

3.7. Quantification of drug content localized to the needle tips of DMN. The quantity of drug localized in the needle tips of DMN was also the critical point for in order to estimate the dose. Accordingly, after the drying process, the amount of ABZ in the needle tips of DMN was further determined. It was found that the amount of ABZ localized in the needle tips of DMN was 3.79 ± 0.51 mg. Therefore, this amount was considered as the dose of ABZ in one DMN array in the further studies.

2.9. Determination of particle size of ABZ-NCs in DMN formulations. The properties of NCs, particularly the particle size and PDI, after the incorporation into DMNs were evaluated. It is important to note that these properties should not be influenced by DMN

preparations. The results showed that in DMN preparations, the properties of ABZ-NCs were observed to be 423 ± 43 nm and 0.26 ± 0.03 for the particle size and PDI, respectively. After statistical analysis, it was found that there were no significantly differences ($p > 0.05$) in these properties in comparison with the initial properties.

3.9. Dissolution study. The *ex vivo* skin dissolution evaluation was carried out to estimate the time needed by DMNs to dissolve completely following application to skin. DMNs containing ABZ-NCs were partially liquefied and showed a decrease in needle height after 10 min of application, as observed in Figure 8. The DMNs reached complete dissolution within 30 min of application to the skin.



Figure 8. *Ex vivo* dissolution profiles the Formulation D at 0 min (**A**), 10 min (**B**), 20 min (**C**) and 30 min (**D**) observed using digital microscope after insertion into and removal from excised neonatal porcine skin.

3.10. Ex vivo dermatokinetic studies. This study was designed to deliver the NCs into the dermis layer, where the drugs would be released for subsequent absorption into the systemic circulation by dermal capillaries. Thus, the release kinetics of ABZ from NCs after being delivered by DMNs into the skin were investigated using *ex vivo* dermatokinetic analysis. This method has been useful to evaluate the *ex vivo* skin kinetic profiles of numerous drugs delivered by DMNs.[27,32,33,68] Needle-free patches were used as a control and were also evaluated for their dermatokinetic profiles. It was discovered that the ABZ concentrations localized in the dermis and epidermis layer after the application of needle-free patches of ABZ were considerably lower ($p < 0.05$) in comparison with the ABZ concentration in the skin layers after the administration of DMNs. Therefore, this result revealed that DMNs could increase the intradermal delivery of ABZ.

Following the penetration of DMNs into the skin, the DMNs absorbs skin interstitial fluid. The polymers are then hydrated and fully dissolved. Afterwards, the drug particles are released and diffuse into the deeper skin layers.[27] Figure 9 presents the comparison of ABZ concentration delivered in the epidermis and dermis after the administration of DMNs compared to the administration of needle-free patch. Moreover, Table 1 presents the dermatokinetic parameters of ABZ following intradermal delivery using DMNs-NCs, namely C_{max}, T_{max}, $T_{1/2}$, AUC and MRT. As shown, the C_{max} values of ABZ following DMNs application were observed to be 415.69 ± 64.31 μg/cm^3 at 2.07 ± 0.29 h and 1891.53 ± 273.83 μg/cm^3 at 2.79 ± 0.41 in the epidermis and dermis, respectively. Furthermore, in the epidermis and the dermis, the AUC values were 10523.40 ± 2732.88 h.μg/cm^3 and 56615.29 ± 8919.79 h.μg/cm^3, respectively. Following statistical analysis, the C_{max} and AUC value of ABZ in the dermis were significantly greater ($p < 0.05$ each) than the value in the epidermis. Importantly, the values of all parameters of dermatokinetic profiles of ABZ after the administration of

needle-free patches were drastically lower ($p < 0.05$) in comparison with the obtained results after DMNs-NCs application.



Figure 9. The ABZ concentration and time profile in epidermis (**A**) and dermis (**B**) layers of excised full-thickness neonatal porcine skin, following the application of DMNs compared to needle-free patches laden with ABZ-NCs (means ± S.D., $n = 3$).

Table 1. The parameters dermatokinetic profiles of ABZ in epidermis and dermis layers of excised full-thickness neonatal porcine skin, following the application of DMNs compared to needle-free patches laden with ABZ-NCs (means ± S.D., $n = 3$).

Parameters	Epidermis	Dermis
C_{max} (μg/cm³)	415.69 ± 64.31	1891.53 ± 273.83
T_{max} (h)	2.07 ± 0.29	2.79 ± 0.41
AUC (h.μg/cm³)	10523.40 ± 2732.88	56615.29 ± 8919.79
$T_{1/2}$ (h)	20.44 ± 4.19	28.13 ± 5.63
MRT (h)	29.99 ± 6.31	41.26 ± 8.17

In addition to the dermatokinetic profiles, the distributions of ABZ in various layers of full-thickness porcine skin were investigated. In this study, three time points, i.e. 1 h, t_{max} of dermatokinetic parameters and 48 h after the administration of DMNs-NCs were chosen. It was found that ABZ was well-localized in various depth of the skin until a depth of 2.5 mm following the application of DMNs-NCs (Figure 10). This study showed that the longer application time was able to result in the increase of ABZ concentration in the lower areas on the skin, indicating the movement of ABZ-NCs in the skin.



Figure 10. The ABZ concentrations localized in the different layers of neonatal porcine skin, following the administration of DMNs containing ABZ-NCs at 1 h (**A**), t_{max} of dermatokinetic profiles (**B**) and 48 h (**C**), in comparison with needle-free patches at 48 h (**3**) (means ± S.D., *n* = 3).

Particularly, the maximum concentrations of ABZ were found to be 211.06 ± 47.19 μg/cm^3, 554.52 ± 121.13 μg/cm^3 and 107.91 ± 19.92 μg/cm^3 at depths of 0.9 mm, 1.3 mm and 1.5 mm, respectively. On the other hand, with respect to needle-free patch distribution, ABZ was only detectable until a depth of 1.1 mm. Additionally, the skin distribution of ABZ after the administration of needle-free patch was found to be statistically lower ($p < 0.05$) compared to DMNs-NCs demonstrating the poor skin distribution after their administrations. The findings obtained in this study exhibited the benefit of the combination of DMNs and NCs in enhancing the delivery of ABZ in the dermis layer, where the drugs are absorbed by blood.[69]

3.11. In vivo studies. As previously discussed, intradermal delivery was considered as the most suitable option to deliver ABZ because this route could potentially circumvent the first-pass metabolism in the liver, avoiding the metabolism of ABZ. In this experiment, the pharmacokinetic parameters of ABZ and its metabolites, ABZ-SX and ABZ-SN in plasma were assessed following being delivered using DMNs-NCs approach. Importantly, we compared the pharmacokinetic profiles of all compounds with the oral administration of ABZ-NC as the conventional administration route of ABZ for CE. Additionally, the pharmacokinetic studies were also performed for DMNs and oral administration for coarse ABZ.

In the *in vivo* experiment, following 24 h, we removed the DMNs from the rats and it was observed that all DMNs were completely dissolved in the rats' skin. We did not observe any signs of irritation on the skin of all the rats. Table 2 and Table 3 present the plasma pharmacokinetic parameters of all analytes in Wistar rats following the intradermal administration of DMNs-ABZ NCs and DMNs-coarse ABZ, as well as the oral administration of ABZ-NCs and coarse ABZ. Concentrations of ABZ, ABZ-SX and ABZ-SN in plasma after the DMNs and oral administration of ABZ-NCs and coarse ABZ are shown in Figure 11.

610 Furthermore, the values of the pharmacokinetic parameters are depicted in Table 2 and Table
611 3.

Table 2. *In vivo* plasma pharmacokinetic parameters of ABZ, ABZ-SX and ABZ-SN post-oral dosing of coarse suspension of ABZ and ABZ-NCs to Wistar rats (means ± SD, n = 3 for each group).

Parameters	Oral-Coarse Suspension			Oral-NCs		
	ABZ	**ABZ-SX**	**ABZ-SN**	**ABZ**	**ABZ-SX**	**ABZ-SN**
C_{max} (μg/mL)	1.52 ± 0.42	1.38 ± 0.29	0.09 ± 0.01	2.43 ± 0.41	2.98 ± 0.51	0.12 ± 0.02
T_{max} (h)	0.5	1	4	0.5	1	2
AUC_{0-72} (h. μg/mL)	0.74 ± 0.12	13.01 ± 2.23	1.02 ± 0.23	10.84 ± 2.31	31.72 ± 6.52	2.07 ± 0.41
AUC_{0-inf}(h. μg/mL)	0.74 ± 0.12	14.01 ± 2.21	1.65 ± 0.28	10.95 ± 2.43	54.22 ± 8.43	3.08 ± 0.54
$T_{1/2}$ (h)	0.88 ± 0.17	13.89 ± 2.24	14.60 ± 2.73	3.54 ± 0.67	48.75 ± 8.04	33.41 ± 6.82
MRT (h)	0.68 ± 0.14	1.08 ± 0.31	9.09 ± 1.02	6.06 ± 1.32	58.03 ± 11.91	43.5 ± 7.49

Table 3. *In vivo* plasma pharmacokinetic parameters of ABZ, ABZ-SX and ABZ-SN following DMNs administration of coarse suspension of ABZ and ABZ-NCs to Wistar rats (means ± SD, n = 3 for each group).

Parameters	DMNs-Coarse Suspension			DMNs-NCs		
	ABZ	**ABZ-SX**	**ABZ-SN**	**ABZ**	**ABZ-SX**	**ABZ-SN**
C_{max} (μg/mL)	0.29 ± 0.06	0.08 ± 0.01	0.06 ± 0.01	0.96 ± 0.32	0.32 ± 0.07	0.06 ± 0.01
T_{max} (h)	24	24	48	6	24	48
AUC_{0-72} (h. μg/mL)	12.09 ± 1.33	2.70 ± 0.43	2.82 ± 0.66	57.59 ± 12.49	16.51 ± 3.62	2.88 ± 0.61
AUC_{0-inf}(h. μg/mL)	20.56 ± 4.01	4.27 ± 0.61	N/A	189.23 ± 33.51	36.03 ± 6.09	N/A
$T_{1/2}$ (h)	43.52 ± 8.09	36.31 ± 7.19	N/A	136.18 ± 21.28	69.38 ± 10.81	N/A
MRT (h)	76.35 ± 18.81	70.31 ± 13.19	N/A	197.44 ± 34.23	110.87 ± 24.09	N/A

With respect to the C_{max} values following oral dosing of coarse suspension, the analytes reached the maximum concentrations at the concentrations of 1.52 ± 0.43 µg/mL for ABZ, 1.38 ± 0.29 µg/mL for ABZ-SX and 0.09 ± 0.01 µg/mL for ABZ-SN. The AUC_{0-72} values were 0.74 ± 0.12 h.µg/mL for ABZ, 13.01 ± 2.23 h.µg/mL for ABZ-SX and 1.02 ± 0.23 ± h. µg/mL for ABZ-SN. Being formulated into NCs, following oral administration, the maximum plasma concentrations of ABZ, ABZ-SX and ABZ-SN were found to be 2.43 ± 0.41 µg/mL, 2.98 ± 0.51 µg/mL and 0.12 ± 0.02 µg/mL, respectively. The AUC_{0-72} values were observed to be 10.84 ± 2.31 h.µg/mL for ABZ, 31.72 ± 6.52 h.µg/mL for ABZ-SX and 2.07 ± 0.41 ± h.µg/mL for ABZ-SN. After DMNs administration of coarse ABZ, the maximum concentrations of 0.29 ± 0.06 µg/mL (AUC_{0-72} value of 12.09 ± 1.33 h.µg/mL), 0.08 ± 0.01µg/mL (AUC_{0-72} value of 2.70 ± 0.43h.µg/mL) and 0.06 ± 0.01 µg/mL (AUC_{0-72} value of 2.82 ± 0.66h.µg/mL) were found for ABZ, ABZ-SX and ABZ-SN, respectively. After ABZ-NCs administration delivered by DMNs, the C_{max} values were calculated to be 0.96 ± 0.32 µg/mL for ABZ, 0.32 ± 0.07 µg/mL for ABZ-SX and 0.06 ± 0.01 µg/mL for ABZ-SN, with AUC_{0-72} values of 57.59 ± 12.49 h.µg/mL, 16.51 ± 3.62 h.µg/mL and 2.88 ± 0.61 h.µg/mL, respectively.



Figure 11. Mean plasma concentrations and time profiles of ABZ, ABZ-SX and ABZ-SN after oral administration of coarse suspension of ABZ (**A**) and ABZ-NCs (**B**), as well as after intradermal administration of coarse ABZ (**C**) and ABZ-NCs (**D**) using DMNs. The relative bioavailability values of ABZ delivered by DMN-NC compared to oral administration of coarse ABZ, oral administration of ABZ-NCs and DMN administration of ABZ-NCs (**E**) (means ± SD, *n* = 3).

As the main purpose of this study was to improve the bioavailability of ABZ, we focused on the pharmacokinetic profiles of ABZ in detail. Analyzed statistically, it was found that the C_{max} of ABZ following oral administration of ABZ-NC and coarse ABZ were statistically greater ($p < 0.05$) in comparison with the C_{max} values after DMN administration. C_{max} is the maximum (or peak) concentration of drug achieved in a specified compartment.[70] Furthermore, the AUC value is a pharmacokinetic parameter utilized in diverse ways according to the background of experimental.[70] In this study, this parameter was used as an index of the total drug exposure integrated over time in the body. Accordingly, AUC values can also be used to determine the amount of drug absorbed or the effectiveness of physiological processes to eliminate the drugs.[70,71] The $t_{1/2}$ represents the time required for half the initial dose of drug administered to be eliminated from the body.[71,72] The MRT refers to the whole persistence of the drugs in the body and is, hence, the mean time that the drugs reside in the body. In this study, it was found that the $t_{1/2}$ values of ABZ following the oral administration of coarse ABZ, the oral administration of ABZ-NCs, the DMN administration of coarse ABZ and the DMN administration of ABZ-NCs were determined to be 0.88 ± 0.17 h, 3.54 ± 0.67 h, 43.52 ± 8.09 h and 136.18 ± 21.28 h, respectively. Moreover, MRT values were found to be 0.68 ± 0.14 h, 6.06 ± 1.32 h, 76.35 ± 18.81 h and 197.44 ± 34.23 h after the oral dosing of coarse ABZ, the oral dosing of ABZ-NCs, the DMN application of coarse ABZ and the DMN application of ABZ-NCs. After statistical analyses, the values of AUC_{0-72}, the $t_{1/2}$, and MRT of ABZ after DMN application of ABZ-NCs were determined to be statistically greater ($p < 0.05$) in comparison with post-oral application. Considering these parameters, despite the lower C_{max}, the intradermal administration of ABZ-NCs by DMNs was able to prolong the systemic exposure of ABZ in the circulation. This may be because the release of the active substance may be sustained following the intradermal administration, leading to the longer systemic circulation.[73] The same trend has been reported earlier, showing that compared to drug

administration *via* oral route, the intradermal administration using DMNs resulted in greater AUC value.[74] It has been reported that cytochrome P450 is also found the skin,[75] also after absorption in the skin the molecules travel in the body, including to the liver the ABZ metabolism happen. Additionally, the microsomes in the skin are able to metabolize known the substrates of P450. In the skin, the activity of this enzyme varied between 2.5% and 13.4% of the activities in the liver. Therefore, small metabolism of ABZ through intradermal route could occur.[75,76] It was also important to note that the pharmacokinetic profiles of ABZ-SX following the oral dosing were considerably greater ($p < 0.05$) compared to the DMN administration, showing that we were able to maintain plasma concentrations of ABZ without being rapidly metabolized into ABZ-SX. Therefore, the intradermal route chosen in our study was able to avoid extensive rapid first-pass metabolism of ABZ in the liver. Without being formulated into NCs, the *in vivo* delivery of ABZ using DMNs was found to be relatively poor. The pharmacokinetic parameter values were observed to be drastically smaller ($p < 0.05$) in comparison with all cohorts in this study. This might be caused by the high deposition of ABZ in the skin. Due to its hydrophobicity, the release of ABZ in the skin was expected to be slow. This was supported by our *in vitro* release discussed previously, showing the slow release profile of ABZ compared to ABZ-NCs. Therefore, the formulation of ABZ into NCs successfully improved the *in vivo* delivery of ABZ into the systemic circulation.

In addition, by comparing the AUC values, we calculated the relative bioavailability of ABZ following intradermal delivery *via* DMNs compared to the administration of both NCs and coarse forms *via* oral route. The results showed that the relative bioavailability values of ABZ delivered by DMN-NC were found to be 7780.33 ± 1562.30 %, 531.16 ± 136.11 % and 476.35 ± 87.11 % when compared to oral administration of coarse ABZ, oral administration of ABZ-NCs and DMN administration of ABZ-NCs, respectively. The relative biovailabilities of ABZ in DMNs-NCs cohort compared to all cohorts were more than 100%, implying the

higher bioavailability of ABZ after NCs formulation delivered by DMNs. These *in vivo* studies showed that the formulation of ABZ into NCs incorporated into DMNs provide two benefits. Firstly, the combination of NCs and DMNs could potentially enhance the bioavailability of ABZ. Secondly, this combination approach was able to avoid the metabolism of ABZ, which could potentially increase the effectiveness of ABZ in the treatment of CE.

According to the results discussed here, the incorporation of the NCs into DMNs was able to improve the bioavailability of ABZ, while avoiding the liver metabolism, as compared to the oral administration. Being delivered by DMNs, this technology is a safe handling, self-administered, painless and the most suitable options for CE treatment, especially the situation where it is extremely challenging to find a healthcare professional to treat this specific disease. Therefore, it is hypothesized that this novel approach could be beneficial as an alternative treatment of CE. The preclinical efficacy of ABZ-NCs in animal model of CE and NCs was evaluated previously using an oral treatment[77], attaining an enhanced but limited therapeutic response against the parasite in chemoprophylaxis (which represents the rupture of the cysts during an extraction surgery) and post-infection (once the infection develops and the treatment is given) experiments.[77] Solid dispersions of ABZ were also analyzed in the same model[78] and lipid nanoparticles[22]. However, all the formulations showed limited efficacy in the CE model. In our study, as discussed previously, we were able to maintain the parent molecule in the circulation for the first time to the best of our knowledge. Therefore, we hypothesize that our findings represent a promising alternative to the current therapy of CE. However, further experiments should be considered, including toxicity studies, biocompatibility studies and an *in vivo* pharmacodynamic study to assess the effectiveness of this novel approach in the treatment of CE.

4. Conclusion

This extensive work has shown the effectiveness of the combination of NCs and DMNs to overcome the issues of ABZ to potentially improve the treatment of CE. The formulation of ABZ into NCs, stabilized with Pluronic® F127, enhanced the dissolution rate of ABZ, while maintaining the crystallinity of the drug. Moreover, the formulation of ABZ-NCs into DMNs with adequate mechanical properties and skin insertion abilities resulted in enhancement of the concentration of ABZ retained in the dermis layer of the skin. Lastly, plasma pharmacokinetic assessment demonstrated that the intradermal delivery of ABZ-NCs delivered by DMNs could increase the relative bioavailability of the parent drug ABZ, and decrease the concentration of its metabolites, namely ABZ-SX and ABZ-SN, in comparison with the administration of coarse ABZ and ABZ-NCs *via* oral route, as well as DMN dosing of coarse ABZ. Therefore, this innovative approach could potentially lead to improvement of CE treatment. To prove its efficacy in the CE treatment, *in vivo* pharmacodynamic study will now be our next step.

AUTHOR INFORMATION

Corresponding Author

Correspondence should be addressed to Professor Ryan F. Donnelly **(**School of Pharmacy, Queen's University Belfast). Email: r.donnelly@qub.ac.uk

Authors

Andi Dian Permana - Department of Pharmaceutics, Faculty of Pharmacy, Hasanuddin University, Makassar 90245, Indonesia

Alejandro J. Paredes - School of Pharmacy, Queen's University Belfast, Belfast, UK BT9 7BL

Fabiana Volpe-Zanutto - School of Pharmacy, Queen's University Belfast, Belfast, UK BT9 7BL; Faculty of Pharmaceutical Sciences, R. Cândido Portinari, 200 - Cidade Universitária, Campinas - SP, 13083-871, University of Campinas, Brazil

Muh. Nur Amir - Department of Pharmacology and Toxicology, Faculty of Pharmacy, Universitas Hasanuddin, Makassar 90245

Ismail Ismail - Department of Phytochemistry, Faculty of Pharmacy, Universitas Hasanuddin, Makassar 90245, Indonesia

Muh. Akbar Bahar - Department of Pharmacology and Toxicology, Faculty of Pharmacy, Universitas Hasanuddin, Makassar 90245

Sumarheni - Department of Clinical Pharmacy, Faculty of Pharmacy, Universitas Hasanuddin, Makassar 90245

Santiago D. Palm - Unidad de Investigación y Desarrollo en Tecnología Farmacéutica (UNITEFA), CONICET and Departamento de Ciencias Farmacéuticas, Facultad de Ciencias Químicas, Universidad Nacional de Córdoba, Argentina. Haya de la Torre y Medina Allende, X5000XHUA, Córdoba, Argentina.

Author Contributions

The manuscript was written through contributions of all authors. All authors have given approval to the final version of the manuscript

Notes

The authors declare no competing financial interest.

ACKNOWLEDGEMENT

This work was supported in part by Wellcome Trust grant number WT094085MA. The authors also thank Mrs. Dewi Primayanti for her support with the analysis of *in vivo* samples.

REFERENCES

(1) Velasco-Tirado, V.; Alonso-Sardón, M.; Lopez-Bernus, A.; Romero-Alegría, Á.; Burguillo, F. J.; Muro, A.; Carpio-Pérez, A.; Muñoz Bellido, J. L.; Pardo-Lledias, J.; Cordero, M.; Belhassen-García, M. Medical Treatment of Cystic Echinococcosis: Systematic Review and Meta-Analysis. *BMC Infect. Dis.* **2018**, *18* (1), 1–19.

(2) Woolsey, I. D.; Miller, A. L. Echinococcus Granulosus Sensu Lato and Echinococcus Multilocularis: A Review. *Res. Vet. Sci.* **2021**, *135* (November 2020), 517–522.

(3) Mandal, S.; Deb Mandal, M. Human Cystic Echinococcosis: Epidemiologic, Zoonotic, Clinical, Diagnostic and Therapeutic Aspects. *Asian Pac. J. Trop. Med.* **2012**, *5* (4), 253–260.

(4) Deplazes, P.; Rinaldi, L.; Alvarez Rojas, C. A.; Torgerson, P. R.; Harandi, M. F.; Romig, T.; Antolova, D.; Schurer, J. M.; Lahmar, S.; Cringoli, G.; Magambo, J.; Thompson, R. C. A.; Jenkins, E. J. Global Distribution of Alveolar and Cystic Echinococcosis. *Adv. Parasitol.* **2017**, *95*, 315–493. https://doi.org/10.1016/bs.apar.2016.11.001.

(5) Labsi, M.; Soufli, I.; Khelifi, L.; Amir, Z. C.; Touil-Boukoffa, C. A Preventive Effect of the Combination of Albendazole and Pomegranate Peel Aqueous Extract Treatment in Cystic Echinococcosis Mice Model: An Alternative Approach. *Acta Trop.* **2019**, *197* (May), 105050.

(6) Zhang, W.; Wen, H.; Li, J.; Lin, R.; McManus, D. P. Immunology and Immunodiagnosis of Cystic Echinococcosis: An Update. *Clin. Dev. Immunol.* **2012**, *2012*. https://doi.org/10.1155/2012/101895.

(7) Butt, A.; Khan, J. The Maverick Disease: Cystic Echinococcosis in Unusual Locations: A Ten Year Experience from an Endemic Region. *Cureus* **2019**, *11* (10). https://doi.org/10.7759/cureus.5939.

(8) Khan, A.; Ahmed, H.; Khan, H.; Saleem, S.; Simsek, S.; Brunetti, E.; Afzal, M. S.; Manciulli, T.; Budke, C. M. Cystic Echinococcosis in Pakistan: A Review of Reported

Cases, Diagnosis, and Management. *Acta Trop.* **2020**, *212* (September), 105709.

(9) Larrieu, E.; Uchiumi, L.; Salvitti, J. C.; Sobrino, M.; Panomarenko, O.; Tissot, H.; Mercapide, C. H.; Sustercic, J.; Arezo, M.; Mujica, G.; Herrero, E.; Labanchi, J. L.; Grizmado, C.; Araya, D.; Talmon, G.; Galvan, J. M.; Sepulveda, L.; Seleiman, M.; Cornejo, T.; Echenique, H.; Del Carpio, M. Epidemiology, Diagnosis, Treatment and Follow-up of Cystic Echinococcosis in Asymptomatic Carriers. *Trans. R. Soc. Trop. Med. Hyg.* **2019**, *113* (2), 74–80.

(10) Brunetti, E.; Kern, P.; Vuitton, D. A. Expert Consensus for the Diagnosis and Treatment of Cystic and Alveolar Echinococcosis in Humans. *Acta Trop.* **2010**, *114* (1), 1–16.

(11) Moro, P.; Schantz, P. M. Echinococcosis: A Review. *Int. J. Infect. Dis.* **2009**, *13* (2), 125–133.

(12) Atayi, Z.; Borji, H.; Moazeni, M.; Saboor Darbandi, M.; Heidarpour, M. Zataria Multiflora Would Attenuate the Hepatotoxicity of Long-Term Albendazole Treatment in Mice with Cystic Echinococcosis. *Parasitol. Int.* **2018**, *67* (2), 184–187.

(13) Walker, M.; Rossignol, J. F.; Torgerson, P.; Hemphill, A. In Vitro Effects of Nitazoxanide on Echinococcus Granulosus Protoscoleces and Metacestodes. *J. Antimicrob. Chemother.* **2004**, *54* (3), 609–616.

(14) Chai, J.; Menghebat; Wei, J.; Deyu, S.; Bin, L.; Jincao, S.; Chen, F.; Xiong, L.; Yiding, M.; Xiuling, W.; Dolikun; Guliber; Yanchun, W.; Fanghua, G.; Shuhua, X. Observations on Clinical Efficacy of Albendazole Emulsion in 264 Cases of Hepatic Cystic Echinococcosis. *Parasitol. Int.* **2004**, *53* (1), 3–10. https://doi.org/10.1016/j.parint.2003.09.015.

(15) Martin, R. J. Modes of Action of Anthelmintic Drugs. *Vet. J.* **1997**, *154* (1), 11–34. https://doi.org/10.1016/S1090-0233(05)80005-X.

(16) Alanazi, F. K.; El-Badry, M.; Ahmed, M. O.; Alsarra, I. A. Improvement of Albendazole Dissolution by Preparing Microparticles Using Spray-Drying Technique.

Sci. Pharm. **2007**, *75* (2), 63–79.

(17) Simonazzi, A.; Cid, A. G.; Paredes, A. J.; Schofs, L.; Gonzo, E. E.; Palma, S. D.; Bermúdez, J. M. Development and in Vitro Evaluation of Solid Dispersions as Strategy to Improve Albendazole Biopharmaceutical Behavior. *Ther. Deliv.* **2018**, *9* (9), 623–638. https://doi.org/10.4155/tde-2018-0037.

(18) Mingjie, W.; Shuhua, X.; Junjie, C.; Bin, L.; Cheng, F.; Weixia, S.; Hotez, P. Albendazole–Soybean Oil Emulsion for the Treatment of Human Cystic Echinococcosis: Evaluation of Bioavailability and Bioequivalence. *Acta Trop.* **2002**, *83* (2), 177–181. https://doi.org/http://dx.doi.org/10.1016/S0001-706X(02)00096-7.

(19) García, J. J.; Bolás, F.; Torrado, J. J. Bioavailability and Efficacy Characteristics of Two Different Oral Liquid Formulations of Albendazole. *Int. J. Pharm.* **2003**, *250* (2), 351–358. https://doi.org/10.1016/S0378-5173(02)00559-8.

(20) Vogt, M.; Kunath, K.; Dressman, J. B. Dissolution Improvement of Four Poorly Water Soluble Drugs by Cogrinding with Commonly Used Excipients. *Eur. J. Pharm. Biopharm.* **2008**, *68*, 330–337. https://doi.org/10.1016/j.ejpb.2007.05.009.

(21) Wen, H.; New, R. R.; Muhmut, M.; Wang, J. H.; Wang, Y. H.; Zhang, J. H.; Shao, Y. M.; Craig, P. S. Pharmacology and Efficacy of Liposome-Entrapped Albendazole in Experimental Secondary Alveolar Echinococcosis and Effect of Co-Administration with Cimetidine. *Parasitology* **1996**, *113 (Pt 2*, 111–121.

(22) Pensel, P. E.; Ullio Gamboa, G.; Fabbri, J.; Ceballos, L.; Sanchez Bruni, S.; Alvarez, L. I.; Allemandi, D.; Benoit, J. P.; Palma, S. D.; Elissondo, M. C. Cystic Echinococcosis Therapy: Albendazole-Loaded Lipid Nanocapsules Enhance the Oral Bioavailability and Efficacy in Experimentally Infected Mice. *Acta Trop.* **2015**, *152*, 185–194.

(23) Abulaihaiti, M.; Wu, X.; Qiao, L.; Lv, H.; Zhang, H. Efficacy of Albendazole-Chitosan Microsphere-Based Treatment for Alveolar Echinococcosis in Mice. **2015**, 1–16. https://doi.org/10.1371/journal.pntd.0003950.

(24) Paredes, A. J.; Llabot, J. M.; Sánchez Bruni, S.; Allemandi, D.; Palma, S. D. Self-Dispersible Nanocrystals of Albendazole Produced by High Pressure Homogenization and Spray-Drying. *Drug Dev. Ind. Pharm.* **2016**, *42* (10), 1564–1570.

(25) Paredes, A. J.; Bruni, S. S.; Allemandi, D.; Lanusse, C.; Palma, S. D. Albendazole Nanocrystals with Improved Pharmacokinetic Performance in Mice. *Ther. Deliv.* **2018**, *9* (2), 89–97. https://doi.org/10.4155/tde-2017-0090.

(26) Paredes, A. J.; Litterio, N.; Dib, A.; Allemandi, D. A.; Lanusse, C.; Bruni, S. S.; Palma, S. D. A Nanocrystal-Based Formulation Improves the Pharmacokinetic Performance and Therapeutic Response of Albendazole in Dogs. *J. Pharm. Pharmacol.* **2018**, *70* (1), 51–58. https://doi.org/10.1111/jphp.12834.

(27) Permana, A. D.; Tekko, I. A.; McCrudden, M. T. C.; Anjani, Q. K.; Ramadon, D.; McCarthy, H. O.; Donnelly, R. F. Solid Lipid Nanoparticle-Based Dissolving Microneedles: A Promising Intradermal Lymph Targeting Drug Delivery System with Potential for Enhanced Treatment of Lymphatic Filariasis. *J. Control. Release* **2019**, *316* (December), 34–52.

(28) Lopez-Garcia, M. L.; Torrado-Duran, S.; Torrado-Duran, J.; Martínez-Fernández, A. R.; Bolás-Fernández, F. Albendazole versus Ricobendazole (Albendazole-Sulphoxide) against Enteral and Parenteral Stages of Trichinella Spiralis in Mice. *Int. J. Parasitol.* **1997**, *27* (7), 781–785.

(29) Daniel-Mwuambete, K.; Ponce-Gordo, F.; Torrado, J.; Torradi, C.; Cuestra-Bandera, C. Effect of Two Formulations of Benzimidazole Carbamates on The Viability of Cysts of Enchinococcus Granulosus In Vivo. *Parasite* **2003**, *10*, 371–373.

(30) Qindeel, M.; Ullah, M. H.; Fakhar-ud-Din; Ahmed, N.; Rehman, A. ur. Recent Trends, Challenges and Future Outlook of Transdermal Drug Delivery Systems for Rheumatoid Arthritis Therapy. *J. Control. Release* **2020**, *327* (September), 595–615.

(31) Ramadon, D.; McCrudden, M. T. C.; Courtenay, A. J.; Donnelly, R. F. Enhancement Strategies for Transdermal Drug Delivery Systems: Current Trends and Applications.

Drug Deliv. Transl. Res. **2021**, No. 0123456789.

(32) Permana, A. D.; McCrudden, M. T. C.; Donnelly, R. F. Enhanced Intradermal Delivery of Nanosuspensions of Antifilariasis Drugs Using Dissolving Microneedles: A Proof of Concept Study. *Pharmaceutics* **2019**, *11* (7), 346.

(33) Permana, A. D.; Mir, M.; Utomo, E.; Donnelly, R. F. Bacterially Sensitive Nanoparticle-Based Dissolving Microneedles of Doxycycline for Enhanced Treatment of Bacterial Biofilm Skin Infection: A Proof of Concept Study. *Int. J. Pharm. X* **2020**, *2*, 100047. https://doi.org/10.1016/j.ijpx.2020.100047.

(34) Paredes, A. J.; Ramöller, I. K.; McKenna, P. E.; Abbate, M. T. A.; Volpe-Zanutto, F.; Vora, L. K.; Kilbourne-Brook, M.; Jarrahian, C.; Moffatt, K.; Zhang, C.; Tekko, I. A.; Donnelly, R. F. Microarray Patches: Breaking down the Barriers to Contraceptive Care and HIV Prevention for Women across the Globe. *Adv. Drug Deliv. Rev.* **2021**, *173*, 331–348. https://doi.org/https://doi.org/10.1016/j.addr.2021.04.002.

(35) Raghava Srivalli, K. M.; Mishra, B. Drug Nanocrystals: A Way toward Scale-Up. *Saudi Pharm. J.* **2016**, *24* (4), 386–404. https://doi.org/10.1016/j.jsps.2014.04.007.

(36) Mohammad, I. S.; Hu, H.; Yin, L.; He, W. Drug Nanocrystals: Fabrication Methods and Promising Therapeutic Applications. *Int. J. Pharm.* **2019**, *562* (December 2018), 187–202. https://doi.org/10.1016/j.ijpharm.2019.02.045.

(37) Keck, C. M.; Müller, R. H. Drug Nanocrystals of Poorly Soluble Drugs Produced by High Pressure Homogenisation. *Eur. J. Pharm. Biopharm.* **2006**, *62*, 3–16.

(38) Mauludin, R.; Müller, R. H.; Keck, C. M. Development of an Oral Rutin Nanocrystal Formulation. *Int. J. Pharm.* **2009**, *370*, 202–209.

(39) Pelikh, O.; Eckert, R. W.; Pinnapireddy, S. R.; Keck, C. M. Hair Follicle Targeting with Curcumin Nanocrystals: Influence of the Formulation Properties on the Penetration Efficacy. *J. Control. Release* **2021**, *329* (October 2020), 598–613.

(40) Shi, C.; Ignjatović, J.; Liu, T.; Han, M.; Cun, D.; Đuriš, J.; Yang, M.; Cvijić, S. In

Vitro - in Vivo - in Silico Approach in the Development of Inhaled Drug Products: Nanocrystal-Based Formulations with Budesonide as a Model Drug. *Asian J. Pharm. Sci.* **2021**, No. xxxx, 1–13.

(41) Permana, A. D.; Nurul, R.; Layadi, P.; Himawan, A.; Juniarti, N.; Kurnia, Q.; Utomo, E.; Aulia, S.; Arjuna, A.; Donnelly, R. F. Thermosensitive and Mucoadhesive in Situ Ocular Gel for Effective Local Delivery and Antifungal Activity of Itraconazole Nanocrystal in the Treatment of Fungal Keratitis. *Int. J. Pharm.* **2021**, *602* (March), 120623.

(42) Pyo, S. M.; Hespeler, D.; Keck, C. M.; Müller, R. H. Dermal Miconazole Nitrate Nanocrystals – Formulation Development, Increased Antifungal Efficacy & Skin Penetration. *Int. J. Pharm.* **2017**, *531* (1), 350–359.

(43) Camiletti, B. X.; Camacho, N. M.; Paredes, A. J.; Allemandi, D. A.; Palma, S. D.; Grosso, N. Self-Dispersible Nanocrystals of Azoxystrobin and Cyproconazole with Increased Efficacy against Soilborne Fungal Pathogens Isolated from Peanut Crops. *Powder Technol.* **2020**, *372*, 455–465. https://doi.org/https://doi.org/10.1016/j.powtec.2020.06.025.

(44) Paredes, A. J.; McKenna, P. E.; Ramöller, I. K.; Naser, Y. A.; Volpe-Zanutto, F.; Li, M.; Abbate, M. T. A.; Zhao, L.; Zhang, C.; Abu-Ershaid, J. M.; Dai, X.; Donnelly, R. F. Microarray Patches: Poking a Hole in the Challenges Faced When Delivering Poorly Soluble Drugs. *Advanced Functional Materials*. 2020, pp 1–27. https://doi.org/10.1002/adfm.202005792.

(45) Romero, G. B.; Keck, C. M.; Müller, R. H. Simple Low-Cost Miniaturization Approach for Pharmaceutical Nanocrystals Production. *Int. J. Pharm.* **2016**, *501*, 236–244.

(46) Mir, M.; Ahmed, N.; Permana, A. D.; Rodgers, A. M.; Donnelly, R. F.; Rehman, A. U. Enhancement in Site-Specific Delivery of Carvacrol against Methicillin Resistant Staphylococcus Aureus Induced Skin Infections Using Enzyme Responsive Nanoparticles: A Proof of Concept Study. *Pharmaceutics* **2019**, *11* (11), 606.

(47) Cordeiro, A. S.; Tekko, I. A.; Jomaa, M. H.; Vora, L.; Mcalister, E.; Volpe-zanutto, F.; Nethery, M.; Baine, P. T.; Mitchell, N.; Mcneill, D. W.; Ryan, F. Two-Photon Polymerisation 3D Printing of Microneedle Array Templates with Versatile Designs: Application in the Development of Polymeric Drug Delivery Systems. *Pharm. Res.* **2020**, *37* (174), 1–15.

(48) Permana, A. D.; Paredes, A. J.; Volpe-Zanutto, F.; Anjani, Q. K.; Utomo, E.; Donnelly, R. F. Dissolving Microneedle-Mediated Dermal Delivery of Itraconazole Nanocrystals for Improved Treatment of Cutaneous Candidiasis. *Eur. J. Pharm. Biopharm.* **2020**, *154* (July), 50–61. https://doi.org/10.1016/j.ejpb.2020.06.025.

(49) Permana, A. D.; Anjani, Q. K.; Sartini; Utomo, E.; Volpe-Zanutto, F.; Paredes, A. J.; Evary, Y. M.; Mardikasari, S. A.; Pratama, M. R.; Tuany, I. N.; Donnelly, R. F. Selective Delivery of Silver Nanoparticles for Improved Treatment of Biofilm Skin Infection Using Bacteria-Responsive Microparticles Loaded into Dissolving Microneedles. *Mater. Sci. Eng. C* **2021**, *120* (October 2020), 111786.

(50) González-Vázquez, P.; Larrañeta, E.; McCrudden, M. T. C.; Jarrahian, C.; Rein-Weston, A.; Quintanar-Solares, M.; Zehrung, D.; McCarthy, H.; Courtenay, A. J.; Donnelly, R. F. Transdermal Delivery of Gentamicin Using Dissolving Microneedle Arrays for Potential Treatment of Neonatal Sepsis. *J. Control. Release* **2017**, *265* (1), 30–40.

(51) McCrudden, M. T. C.; Larrañeta, E.; Clark, A.; Jarrahian, C.; Rein-Weston, A.; Lachau-Durand, S.; Niemeijer, N.; Williams, P.; Haeck, C.; McCarthy, H. O.; Zehrung, D.; Donnelly, R. F. Design, Formulation and Evaluation of Novel Dissolving Microarray Patches Containing a Long-Acting Rilpivirine Nanosuspension. *J. Control. Release* **2018**, *292* (7), 119–129.

(52) Zhang, Y.; Huo, M.; Zhou, J.; Xie, S. PKSolver: An Add-in Program for Pharmacokinetic and Pharmacodynamic Data Analysis in Microsoft Excel. *Comput. Methods Programs Biomed.* **2010**, *99* (9), 306–314.

(53) Paredes, A. J.; Camacho, N. M.; Schofs, L.; Dib, A.; Zarazaga, M. del P.; Litterio, N.;

Allemandi, D. A.; Sánchez Bruni, S.; Lanusse, C.; Palma, S. D. Ricobendazole Nanocrystals Obtained by Media Milling and Spray Drying: Pharmacokinetic Comparison with the Micronized Form of the Drug. *Int. J. Pharm.* **2020**, *585*, 119501. https://doi.org/https://doi.org/10.1016/j.ijpharm.2020.119501.

(54) Melian, M. E.; Paredes, A.; Munguía, B.; Colobbio, M.; Ramos, J. C.; Teixeira, R.; Manta, E.; Palma, S.; Faccio, R.; Domínguez, L. Nanocrystals of Novel Valerolactam-Fenbendazole Hybrid with Improved in Vitro Dissolution Performance. *AAPS PharmSciTech* **2020**, *21* (7), 237. https://doi.org/10.1208/s12249-020-01777-y.

(55) Keck, C. M.; Müller, R. H. Size Analysis of Submicron Particles by Laser Diffractometry--90% of the Published Measurements Are False. *Int. J. Pharm.* **2008**, *355* (1–2), 150–163. https://doi.org/10.1016/j.ijpharm.2007.12.004.

(56) Van Eerdenbrugh, B.; Van den Mooter, G.; Augustijns, P. Top-down Production of Drug Nanocrystals: Nanosuspension Stabilization, Miniaturization and Transformation into Solid Products. *International Journal of Pharmaceutics*. 2008. https://doi.org/10.1016/j.ijpharm.2008.07.023.

(57) Liu, P.; Rong, X.; Laru, J.; Van Veen, B.; Kiesvaara, J.; Hirvonen, J.; Laaksonen, T.; Peltonen, L. Nanosuspensions of Poorly Soluble Drugs: Preparation and Development by Wet Milling. *Int. J. Pharm.* **2011**, *411* (1–2), 215–222.

(58) Abdelbary, A. A.; Al-Mahallawi, A. M.; Abdelrahim, M. E.; Ali, A. M. A. Preparation, Optimization, and in Vitro Simulated Inhalation Delivery of Carvedilol Nanoparticles Loaded on a Coarse Carrier Intended for Pulmonary Administration. *Int. J. Nanomedicine* **2015**, *10* (1), 6339–6353.

(59) Permana, A. D.; Utami, R. N.; Courtenay, A. J.; Manggau, M. A.; Donnelly, R. F.; Rahman, L. Phytosomal Nanocarriers as Platforms for Improved Delivery of Natural Antioxidant and Photoprotective Compounds in Propolis: An Approach for Enhanced Both Dissolution Behaviour in Biorelevant Media and Skin Retention Profiles. *J. Photochem. Photobiol. B Biol.* **2020**, *205*, 111846.

(60) Dash, S.; Murthy, P. N.; Nath, L.; Chowdhury, P. Kinetic Modelling on Drug Release from Controlled Drug Delivery Systems. *Acta Pol. Pharm. - Drug Res.* **2010**, *67* (3), 217–223.

(61) Ramöller, I. K.; Tekko, I. A.; McCarthy, H. O.; Donnelly, R. F. Rapidly Dissolving Bilayer Microneedle Arrays – A Minimally Invasive Transdermal Drug Delivery System for Vitamin B12. *Int. J. Pharm.* **2019**, *566*, 299–306.

(62) Larrañeta, E.; Moore, J.; Vicente-Pérez, E. M.; González-Vázquez, P.; Lutton, R.; Woolfson, A. D.; Donnelly, R. F. A Proposed Model Membrane and Test Method for Microneedle Insertion Studies. *Int. J. Pharm.* **2014**, *472*, 65–73. https://doi.org/10.1016/j.ijpharm.2014.05.042.

(63) McCrudden, M. T. C.; Alkilani, A. Z.; McCrudden, C. M.; McAlister, E.; McCarthy, H. O.; Woolfson, A. D.; Donnelly, R. F. Design and Physicochemical Characterisation of Novel Dissolving Polymeric Microneedle Arrays for Transdermal Delivery of High Dose, Low Molecular Weight Drugs. *J. Control. Release* **2014**, *180* (1), 71–80.

(64) Donnelly, R. F.; Moffat, K.; Alkilani, A. Z.; Vicente-Pérez, E. M.; Barry, J.; McCrudden, M. T. C.; Woolfson, A. D. Hydrogel-Forming Microneedle Arrays Can Be Effectively Inserted in Skin by Self-Application : A Pilot Study Centred on Pharmacist Intervention and a Patient Information Leaflet. *Pharm. Res.* **2014**, *31* (1), 1989–1999.

(65) Donnelly, R. F.; Garland, M. J.; Morrow, D. I. J.; Migalska, K.; Raghu, T.; Singh, R.; Majithiya, R.; Woolfson, A. D. Optical Coherence Tomography Is a Valuable Tool in the Study of the Effects of Microneedle Geometry on Skin Penetration Characteristics and In-Skin Dissolution. *J. Control. Release* **2010**, *147* (3), 333–341.

(66) Lutton, R. E. M.; Larrañeta, E.; Kearney, M. C.; Boyd, P.; Woolfson, A. D.; Donnelly, R. F. A Novel Scalable Manufacturing Process for the Production of Hydrogel-Forming Microneedle Arrays. *Int. J. Pharm.* **2015**, *494* (1), 417–429.

(67) Vora, L. K.; Vavia, P. R.; Larrañeta, E.; Bell, S. E. J.; Donnelly, R. F. Novel

Nanosuspension-Based Dissolving Microneedle Arrays for Transdermal Delivery of a Hydrophobic Drug. *J. Interdiscip. Nanomedicine* **2018**, *3* (2), 89–101.

(68) Volpe-Zanutto, F.; Ferreira, L.; Permana, A. D.; Kirkby, M.; Paredes, A. J.; Vora, L.; Bonfanti, A.; Charlie-Silva, I.; Raposo, C.; Figueiredo, M. C.; Souza, I. M. O.; Brisibe, A.; Costa, F. D.; Donnelly, R. F.; Foglio, M. A. Artemether and Lumefantrine Dissolving Microneedle Patches with Improved Pharmacokinetic Performance and Antimalarial Efficacy in Mice Infected with Plasmodium Yoelii. *J. Control. Release* **2021**, *333*, 298–315.

(69) Permana, A. D.; Nainu, F.; Moffatt, K.; Larrañeta, E.; Donnelly, R. F. Recent Advances in Combination of Microneedles and Nanomedicines for Lymphatic Targeted Drug Delivery. *Wiley Interdiscip. Rev. Nanomedicine Nanobiotechnology* **2021**, No. April 2020, 1–22.

(70) Hinderliter, P.; Saghir, S. A. Pharmacokinetics. *Encycl. Toxicol. Third Ed.* **2014**, *87*, 849–855.

(71) Pirmohamed, M. Pharmacogenetics for the Prescriber. *Med. (United Kingdom)* **2016**, *44* (7), 412–415.

(72) Panchagnula, R.; Thomas, N. S. Biopharmaceutics and Pharmacokinetics in Drug Research. *Int. J. Pharm.* **2000**, *201* (2), 131–150.

(73) Vora, L. K.; Moffatt, K.; Tekko, I. A.; Paredes, A. J.; Volpe-Zanutto, F.; Mishra, D.; Peng, K.; Raj Singh Thakur, R.; Donnelly, R. F. Microneedle Array Systems for Long-Acting Drug Delivery. *Eur. J. Pharm. Biopharm.* **2021**, *159* (December 2020), 44–76. https://doi.org/10.1016/j.ejpb.2020.12.006.

(74) Zhang, S.; Qin, G.; Wu, Y.; Gao, Y.; Qiu, Y.; Li, F.; Xu, B. Enhanced Bioavailability of L-Carnitine after Painless Intradermal Delivery vs. Oral Administration in Rats. *Pharm. Res.* **2011**, *28* (1), 117–123.

(75) Venkatesh, K.; Levi, P. E.; Inman, A. O.; Monteiro-Riviere, N. A.; Misra, R.; Hodgson, E. Enzymatic and Immunohistochemical Studies on the Role of Cytochrome

P450 and the Flavin-Containing Monooxygenase of Mouse Skin in the Metabolism of Pesticides and Other Xenobiotics. *Pestic. Biochem. Physiol.* **1992**, *43* (1), 53–66. https://doi.org/10.1016/0048-3575(92)90019-V.

(76) Ahmad, N.; Mukhtar, H. Cytochrome P450: A Target for Drug Development for Skin Diseases. *J. Invest. Dermatol.* **2004**, *123* (3), 417–425. https://doi.org/10.1111/j.0022-202X.2004.23307.x.

(77) Pensel, P.; Paredes, A.; Albani, C. M.; Allemandi, D.; Sanchez Bruni, S.; Palma, S. D.; Elissondo, M. C. Albendazole Nanocrystals in Experimental Alveolar Echinococcosis: Enhanced Chemoprophylactic and Clinical Efficacy in Infected Mice. *Vet. Parasitol.* **2018**, *251*, 78–84. https://doi.org/10.1016/j.vetpar.2017.12.022.

(78) Pensel, P. E.; Castro, S.; Allemandi, D.; Bruni, S. S.; Palma, S. D.; Elissondo, M. C. Enhanced Chemoprophylactic and Clinical Efficacy of Albendazole Formulated as Solid Dispersions in Experimental Cystic Echinococcosis. *Vet. Parasitol.* **2014**, *203* (1–2), 80–86. https://doi.org/10.1016/j.vetpar.2014.01.027.

1076 **Table of Content Graphic**

1077



BUKTI ACCEPTED

Universitas Hasanuddin

Andi Dian Permana <andi.dian.permana@farmasi.unhas.ac.id>

Fwd: Decision on Manuscript ID am-2021-111796.R2

1 message

Andi Permana <apermana01@qub.ac.uk> Fri, Apr 7, 2023 at 10:09 PM
To: Andi Dian Permana <andi.dian.permana@farmasi.unhas.ac.id>

Get Outlook for iOS

From: Andi Permana <apermana01@qub.ac.uk>
Sent: Tuesday, July 27, 2021 5:14:39 PM
To: Ryan Donnelly <R.Donnelly@qub.ac.uk>; Alejandro Paredes <A.Paredes@qub.ac.uk>; Fabiana Volpe Zanutto <F.VolpeZanutto@qub.ac.uk>
Subject: Re: Decision on Manuscript ID am-2021-111796.R2

Thank you all

Best wishes,
Dian

From: Ryan Donnelly <R.Donnelly@qub.ac.uk>
Sent: 27 July 2021 08:39
To: Andi Permana <apermana01@qub.ac.uk>; Alejandro Paredes <A.Paredes@qub.ac.uk>; Fabiana Volpe Zanutto <F.VolpeZanutto@qub.ac.uk>
Subject: Fw: Decision on Manuscript ID am-2021-111796.R2

Very well done!

Professor Ryan F. Donnelly
Chair in Pharmaceutical Technology
School of Pharmacy
Queen's University Belfast
Medical Biology Centre
97 Lisburn Road
Belfast
BT9 7BL
UK
Tel: +44 (0) 2890 972 251
Fax: +44 (0) 2890 247 794
Email: r.donnelly@qub.ac.uk

From: ACS Applied Materials & Interfaces <onbehalfof@manuscriptcentral.com>
Sent: 27 July 2021 01:24
To: Ryan Donnelly <R.Donnelly@qub.ac.uk>
Subject: Decision on Manuscript ID am-2021-111796.R2

26-Jul-2021

Journal: ACS Applied Materials & Interfaces
Manuscript ID: am-2021-111796.R2
Title: "Albendazole nanocrystal-based dissolving microneedles with improved pharmacokinetic performance for enhanced treatment of cystic echinococcosis"

Authors: Permana, Andi Dian; Paredes, Alejandro; Zanutto, Fabiana Volpe; Amir, Muh. Nur; Ismail, Ismail; Bahar, Muh. Akbar; Sumarheni, Sumarheni; Palma, Santiago Daniel; Donnelly, Ryan F.
Manuscript Status: Accept

Dear Dr. Donnelly:

We are pleased to inform you that your manuscript has been accepted for publication in ACS Applied Materials & Interfaces.

You will soon receive an email invitation from the ACS Journal Publishing Staff that contains a link to the online Journal Publishing Agreement. Please sign and submit the journal publishing agreement within 48 hours.

Your manuscript has been forwarded to the ACS Publications office. You will be contacted in the near future by the ACS Journal Publishing Staff regarding the proofs for your manuscript.

After you approve your proofs, your manuscript will be published on the Web in approximately 48 hours. In view of this fast publication time, it is important to review your proofs carefully. Once a manuscript appears on the Web it is considered published. Any change to the manuscript once it appears on the Web will need to be submitted to the journal office as additions or corrections.

Once your paper is published, you can track downloads and citations of your work by logging into the ACS Publishing Center (https://eur02.safelinks.protection.outlook.com/?url=https%3A%2F%2Fpubs.acs.org%2Fpublish%2Fdashboard&data=04%7C01%7CR.Donnelly%40qub.ac.uk%7C98f2a6c5f0574a288b8f08d95094de6d%7Ceaab77eab4a549e3a1e8d6dd23a1f286%7C0%7C0%7C637629422587200591%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C1000&sdata=hULcHevmAN9ta136E4ISDOaZHEcxQoknDFfYxh6i4XA%3D&reserved=0) and selecting “Published”.

Sincerely,

Prof. Albena Ivanisevic
Associate Editor
ACS Applied Materials & Interfaces
Fax: 12023509587
email: ivanisevic-office@ami.acs.org

TWITTER: ACS Applied Materials & Interfaces has a Twitter account (@ACS_AMI). If you would like us to tweet about your article when it appears on ASAP, please recommend a tweet of less than 200 characters to Charley James and Laura Fernandez at ami-social@ami.acs.org, with your Manuscript ID number (e.g., am-2020-XXXXXX) as the subject line. Include any relevant Twitter handles you would like to include; you do not need to include any DOI or URL information. If you wish to use a graphic other than the TOC graphic, please send it as an attachment. We may modify the tweet before posting, and we may not be able to include all tweets submitted. We appreciate your willingness to provide the tweet within one week of receipt of this email.

Thank you.